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ABSTRACT 
 
MARTHA JANE FELINI: Reproductive Factors and Hormonal Use and  
DNA Repair Polymorphisms XRCC1 and MGMT and Adult-Onset Gliomas 
(Under the direction of Andy Olshan) 
 
    Gliomas are the most common and potentially most fatal of brain tumors.  With few leads emerging, focus 
has reshifted to the consistent predisposition of glial tumors toward males.  Previous studies using reproductive 
factors to evaluate whether hormones may play a role in gliomagenesis have been largely inconclusive.  Using 
the population-based San Francisco Adult Glioma Study, we evaluated whether reproductive factors and 
exogenous hormone use were independently associated with gliomas and went further to evaluate cumulative 
exposure.  Overall, reproductive and menstrual factors were not associated with gliomas.  However, inverse 
associations were observed for ever exogenous hormone use (oral contraceptive use (OC): adjusted odd ratio 
(AOR) = 0.73, 95% CI, 0.49-1.10; postmenopausal hormone use (PHT): AOR = 0.53, 95% CI: 0.33-0.86).  Risk 
estimates decreased with increasing duration of OC use among ever users.  OC users who subsequently used 
PHT were at significantly reduced risk of gliomas (AOR = 0.45, 95% CI: 0.21-0.99), but departures from the 
multiplicative and additive scales were not statistically significant.  Cumulative exposure was defined multiple 
ways and showed no clear pattern of association.  Analysis by smoking status and histologic subtype was 
unrevealing. 
    As a second line of investigation, we used the same parent study to evaluate whether DNA repair 
polymorphisms XRCC1 Arg399Gln, MGMT Leu84Phe, and MGMT Ile143Val were associated with gliomas 
among male and female participants.  Significant associations were not found between XRCC1 and MGMT 
polymorphisms and gliomas.  The adjusted odds ratio of the XRCC1 399Gln variant among whites was 0.96 
(95% CI, 0.72-1.28).  A weak positive association (AOR = 1.26; CI, 0.90-1.75) was observed for the MGMT 
Leu84Phe polymorphism (Leu or Phe/Phe versus Leu/Leu), an association that was stronger among males 
(AOR = 1.75; CI,1.12-2.74) and non-glioblastoma cases (AOR = 1.54; CI, 1.02-2.34).  DNA repair 
polymorphisms did not notably modify risk estimates for the smoking-glioma association, suggesting little
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evidence of a multiplicative or additive joint effect between genotypes and cigarette smoking.  Two way gene-
gene interactions of XRCC1 and previously associated ERCC1 and ERCC2 repair genes were unremarkable.    
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CHAPTER I: BACKGROUND 
A. Introduction         
    Brain tumors are among the most debilitating, progressive, and fatal of all cancers.  Of the nearly 19,000 
cases of primary malignant brain tumors expected to be diagnosed this year in the US, an estimated 70% are 
expected to die within 1-5 years accentuating the disproportionate number of years of life lost compared to 
other cancers.1 With a near zero cure rate and 5 year survival rates less than 30%, the burden of these tumors is 
considerable for the individuals, their families, and the health care system.  For example, patients with brain 
tumors accrue 23 times higher total healthcare costs than their counterparts without cancer2 and experience more 
than three times as much loss of life, making it the leading cancer site whose population burden will exceed its 
simple mortality.3 Recent evidence suggests that the incidence of gliomas, the largest group of brain tumors, is 
increasing,4,5 but perhaps not among premenopausal women.4,6 Whether this is a true reflection of disease or due 
to improved diagnostic procedures, changing classification systems, or greater access to medical care is difficult 
to confirm. However, observations that other brain tumor subtypes are more common in women than men 
suggest that differences in glioma incidence may be due to issues of basic biology rather than health care 
access.7,8   
    Although not a particularly novel hypothesis, the relationship between reproductive factors and gliomas is 
one that continues to elude investigators well into 35 years.  Recent advances in molecular biology have 
increased our knowledge of how hormones target the central nervous system and have uncovered explanations 
for seemingly contradictory findings in observational studies, specifically in relation to estrogen function, but 
questions still remain.  The preponderance of evidence describes estrogen as contributing to the carcinogenic 
mechanism either directly through formation of phenoxyl and semiquinone radicals as demonstrated in the 
hamster kidney tumor model or indirectly through oxygen radicals.9  Despite its carcinogenic effect in most 
tissues, estrogens function in the brain is not entirely known.  Studies of neurodegenerative disease and 
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cardiovascular disease do not support estrogen as causing a purely carcinogenic effect.  There are multiple 
potentially neuroprotective pathways which are associated with estrogens and some metabolites that have been 
shown to decrease tumorigenesis, but how these pathways interact with pathways promoting the carcinogenic 
effects of estrogen is not understood.  Preliminary evidence suggests a delicate balance between estrogens 
prooxidant and antioxidant activities in the brain.   
    Previous studies have been limited in measuring hormone levels directly due to the logistic difficulties of 
obtaining repeated serum samples required to track hormone variability throughout the generally long latency 
period typically associated with cancers.  On the basis that pregnancy, menarche and menopause are sentinel 
events of large hormonal fluctuations in women, variables such as gravidity, parity, age at first birth, age at 
menarche and menopause, and exogenous hormone use have been used as crude surrogates of hormone 
exposure in a wide range of cancers.  Epidemiologic studies investigating glioma risk using these surrogates 
have been generally inconsistent, except for exogenous hormone use which consistently demonstrate odds ratios 
below the null.  Parity and earlier age at menarche appear to confer a protective effect, but later age at 
menopause does not.  This seemingly contradictory finding may be attributed to the differences in origin of sex 
hormones (e.g. exogenous, postmenopausal, premenopausal) or predilection of tumor location in menopausal 
women to regions of the brain insensitive to female hormones.  Differences may be more likely due to 
methodologic issues such as the high number of proxy respondents, combining subtypes of gliomas with 
distinct etiologies into one disease category, small case numbers limiting detection of weak effects, or the poor 
reliability of reproductive factors as surrogates for endogenous hormone levels.   
    With few environmental leads emerging as risk factors for gliomas, evidence suggests that genetic 
susceptibility may play a major role.  Hereditary syndromes and familial inheritance account for a relatively 
small proportion of cases.  Genetic polymorphisms of repair genes, which are less penetrant but more common, 
may be of more relevance to glioma susceptibility.  DNA repair polymorphisms ERCC1 (C→A at codon 8092) 
and ERCC2 (C→A at codon 156), have previously been shown to increase risk of gliomas.1,2 Given that ERCC1 
at codon 8092 and ERCC2 at codon 156 are silent mutations, both may either serve as a proxy for the true 
susceptibility allele or may function to modify the effect of a more important gene in another repair pathway 
that would result in a more damaging amino acid substitution.3 One likely candidate is the XRCC1 (X-ray cross 
complementing group 1) gene, a well conserved base excision repair (BER) gene involved in repairing strand 
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breaks caused by oxidative radicals and residing in the same region as ERCC1/ERCC2 and putative tumor 
suppressor genes GLTSCR1 and GLTSCR2. The XRCC1 Arg399Gln polymorphism involves an amino acid 
change at an evolutionarily conserved region that could alter XRCC1 function.4  
    Another DNA repair gene of interest is O6-methylguanine-DNA methyltransferase (MGMT), a pivotal DNA 
repair enzyme that protects cells primarily from alkylating agents which are putative risk factors of gliomas. 
Once induced, MGMT directly and specifically removes alkyl DNA adducts at the O6 position of guanine thus 
preventing a nucleotide transition. Loss of MGMT expression, typically as a result of promoter methylation, can 
lead to point mutations, sister chromatid exchanges and chromosomal aberrations.  Molecular epidemiologic 
studies of brain tumors suggest nearly half of gliomas demonstrate MGMT methylation.5  Several MGMT 
polymorphisms have been identified and marginally associated with lung, bladder, and esophageal cancers.  Of 
interest in this study are polymorphisms resulting in an amino acid substitution at codons 84 and 143.   
B.  Classification of gliomas 
  
    Over 160 different types of brain tumors have been identified,1 each of which may have different causal 
factors, grades, and location preferences.  Categorization of these tumors into universally accepted classification 
and grading systems has yet to be accomplished largely due to the histologic heterogeneity between and within 
tumors as well as the subjective analysis of tumor specimens.6,7 Yet, it is important to distinguish between glial 
tumor subtypes as each is thought to evolve from distinct genetic pathways.8,9  The majority of primary brain 
tumors are included under the general classification of gliomas, named after the cells which they most resemble.  
The fundamental types of glial cells in the brain are astrocytes, oligodendrocytes, and ependymal cells.  Brain 
tumors containing more than one of these cell types are classified as mixed gliomas.  In reality, this method of 
classification provides only a standard for communication as most gliomas demonstrate heterogeneity of cell 
types between tumors and within single tumors.10  Glial tumors can be further subdivided by grading systems 
based on a three-tiered (low, mid-grade, or high grade) or a four tiered system (I, II, III, IV), in order of 
increasing malignancy.  Though low grade gliomas are presumed to carry a better prognosis, they may be just as 
fatal as high grade tumors if located in critical areas of the brain.11,12   
C. Descriptive epidemiology 
 
    The demographic factors most associated with glioma incidence are male sex, advancing age, and Caucasian 
race, none offering potential for preventive interventions. Incidence rates for gliomas (International 
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Classification of Diseases for Oncology, morphology codes 9380-9481) are over 1.5 times greater in males 
compared to females (9.2 per 100,000 person-years vs. 6.0 per 100,000 person-years, respectively).1  Diagnosis 
of new cases appears to occur at a younger age in males than females (figure 1.1).  Five year survival rates for 
gliomas demonstrate a female advantage (25.4% vs. 23.6%), though the difference appears less pronounced 
following menopause.13  
    A bimodal age distribution is characteristic of brain tumors with a peak incidence in the early half of the first 
decade of life and a second peak in the fourth decade.  The mean age for adult onset gliomas is 54, but age 
distributions differ between histologic tumor types. (Table 1.1) 
    Gliomas are twice as common in whites than blacks while rates are lowest for Alaskan natives, American 
Indians, and Asians.1  Incidence rate ratios for all glioma subtypes range from 1.8 to 3.5 times greater in whites 
than among African-Americans and Hispanics.  A male predominance persists across all races at nearly 
identical ratios (male:female = 1.5) suggesting that variables such as health care access and socioeconomic 
status cannot fully explain the gender differences.   
    International comparisons indicate the US glioma incidence rates are higher than most world countries, but 
are similar to other affluent high risk countries such as Europe and Australia.8,23 Immigrants moving to the US 
generally assume the increased risk of glioma.  Whether this increase is due to environmental risk factors or as a 
result of better diagnostic services and registration systems is unknown.8 It is striking to note that male excess in 
brain tumor incidence and mortality rates remains across international geographic regions, regardless of 
industrialization or socioeconomic development, offering further support of a relevant endogenous exposure 
common among population subgroups in different geographic locations.14 
    Despite investigations into environmental, occupational, and infectious exposures and lifestyle habits, the 
majority of evidence does not strongly nor consistently implicate any one risk factor that would explain the 
majority of glioma cases.  No exogenous environmental mutagen apart from the rare exposure to high-dose 
ionizing radiation has been identified in relation to gliomas. (Table 1.2)  Only 1-2% of gliomas can be explained 
by genetic syndromes, and an equally small proportion by familial inheritance.  The influence of endogenous 
exposures such as hormones and genetic events may be better able to explain the greater majority of gliomas 
since both are ubiquitous by nature. 
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D.  Manuscript 1:  Reproductive factors and hormone use and gliomas 
 
1. Evidence of hormonal influence on gliomas 
 
    Sex hormones are primarily produced by the gonads and adrenal glands and transferred to the brain via the 
blood stream.  Some hormones can be formed directly in the brain either by metabolism of circulating hormones 
or by synthesis from cholesterol.  Hormone receptors are widely distributed in brain tissue confirming a 
functional system for hormonal activity in the brain.15,16 Hormones regulate the development and function of the 
brain primarily through glial cells which, among other tasks, serve to synthesize active hormonal metabolites, 
modulate hormonal secretion, and mediate hormonal signaling.17 In addition, hormones participate in several 
physiological and pathological processes in the brain, including the regulation of tumor cell growth.18  
    Cell cultures and animal studies provide strong evidence of a hormonal influence on gliomas.  Cell cultures 
demonstrate that estrogen directly inhibits glioblastoma cell lines and inhibits regulation of glial cell growth, 
adhesion, and morphology.26,19  Rodent studies have reproducibly identified hormone receptors in normal glial 
cells 20 and a highly significant female advantage in glioma incidence, growth, and survival among both 
transplanted and spontaneously occurring tumors.21,22 In a sentinel study, tumor growth was directly inhibited by 
the presence of exogenous or endogenous estrogen in nude rats implanted with a human glioblastoma line.23 
Experiments removing the ovaries from female animals demonstrated survival rates that mirrored those of male 
animals.  When given estrogen replacement, ovarectomized animals were restored to their original survival 
advantage.24 
    Several epidemiologic studies have found a hormonal influence on non-hormonal cancers: colon cancer,25 
pancreatic cancer,26,27 bone degeneration,28,29 glaucoma,30 systemic lupus erythematosus,31 Hodgkins disease,32 
cardiovascular disease, 33,34,35 and neurodegenerative disease.36,37,38 Investigators have been hesitant to 
acknowledge the hormonal impact of female sex hormones on gliomas primarily because estrogen and progestin 
receptors are either not observed in glial tumors or are present in low concentrations.  Explanations for this are 
not readily evident; however, there is growing literature regarding the neuroprotective effects of estrogen acting 
through estrogen receptor independent pathways.9,39,40,41 Another plausible explanation is that male sex 
hormones, not female hormones, may be driving the disproportionate rates between genders, given that 
androgen receptors are readily apparent in gliomas.42,43,44,45,46,47   
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2.  Mechanisms of hormonal influence on gliomas 
    Precise regulation of glial cell cycles is under the control of signaling pathways to ensure proper cell growth 
and function.  The most commonly activated signaling cascades in gliomas are the AKT/PIP and 
RAS/MAPK/Rb/CDK pathways.48  Mutations of genes in these pathways result in uncontrolled signaling 
leading to unscheduled growth and transition to tumor cells.  Mitogens initiate Ras/MAPK pathways signaling 
the transcription of cyclin D1 which complexes with CDKs promoting phosphorylation of RB and subsequent 
unscheduled entry into the cell cycle.  Previous studies have demonstrated that estrogen can inhibit cell cycle 
entry by increasing MAPK levels in astrocytes.  Interestingly, lower amounts of estrogen were needed to 
activate higher levels of MAPK in astrocytes of females than males.49, 50 Moreover, estrogen significantly 
decreased DNA synthesis in female but not male astrocytes. Thus gender appears to impact the effect of 
estrogen on astrocyte proliferation and death in the brain mediated at least in part by this signaling pathway.  
The AKT/PIP signaling pathway interacts and cross-regulates with the Ras/MAPK/Rb/Cdk pathway to assist in 
cell cycle control.51,52  Previous studies have demonstrated that estrogen can stimulate the AKT/PIP pathway 
independently of growth factors.26,58 The role of progesterone in these pathways is unknown. 
    The effects of estrogen in the brain may be mediated by the activation of growth factor signaling.  Substantial 
evidence implicates tumor growth factor beta I (TGF-β1) and insulin growth factor I (IGF-I).  In vivo and in 
vitro studies demonstrate an estrogen-astrocyte-TGF-β1 pathway as a plausible pathway in mediating the 
protective effects of estrogen in the brain.53,54,55,56 Astrocytes exposed to excitotoxins produce and release TGF-
β1, a potent neuroprotective factor in most organs.57  In the presence of estrogen receptors, estrogen enhances 
the release of TGF- β1 via mediation by the AKT/PIP signaling pathway.58  Neighboring ER-negative glial cells 
may indirectly benefit from TGF- β1 release.  Another growth factor whose actions in the brain are 
interdependent with estrogen is IGF-I.59  Both have been found to work synergistically to increase AKT activity 
and induce bcl-2 factors in the rat brain.67  In-vivo studies reported the neuroprotective effects of estradiol were 
blocked by an IGF-IR antagonist, while the neuroprotective effect of IGF-I was blocked by an ER antagonist.  
These findings suggest activation of both ER and IGF-IR is necessary for neuroprotection.60  
    Although estrogen is a known cancer causing agent, not all forms of the hormone are carcinogenic.  Estrogen 
metabolites have been shown to generate both prooxidant and antioxidant properties61 depending on the location 
of the target cells within the brain and their concentrations.62,63,64,65,66 Therefore, it is plausible that it is not 
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estrogen per se, but an active metabolite that causes the female advantage in gliomas, such as 2-
methoxyestradiol (2ME2).  In vitro, 2ME2 inhibits the growth of a wide variety of cell lines and cultures; in 
vivo, it has been shown to be an effective inhibitor of tumor growth and angiogenesis.67,68,69,70 In an experiment 
implanting human GBM lines into nude rats, 2ME2 acted as a significant inhibitor of glioblastomas.32 
Furthermore, the actions of 2ME2 are independent of estrogen receptors.77 Plasma levels of 2ME2 in women are 
high compared with men and can be even more elevated during pregnancy.71 It remains unclear the role of other 
estrogen metabolites known to cause DNA mutations, but polymorphisms of genes involved in hormone 
metabolism (e.g. CYP2E1) have been only weakly associated with glioma risk.72  
    Whether estrogen and progesterone have separate and distinct effects on glioma susceptibility is unknown. 
Speculation of an independent progesterone effect originated from observations of pregnancy related gliomas 
typically presenting in the first trimester, not later trimesters when progesterone levels spike.73,74  Preliminary 
studies uncovered a possible mechanism via progesterones indirect role in regulating angiogenesis.  
Angiogenesis is a vital component of the development and progression of brain tumors. Notably, GBM is one of 
the most highly vascularized solid tumors. Rodent studies suggest that placental hormones released during 
pregnancy may be responsible for restricting tumor angiogenesis and limiting tumor growth systemically.75 
Progesterone induces the release of proliferin-related protein (PRP) during the later trimesters of pregnancy 
explaining, perhaps in part, the protective effect of giving birth and agreeing with previous studies failing to 
find the same beneficial effect by just being pregnant.  As with estrogen, progesterone has a dual function acting 
as a tumor promoter or inhibitor. 76 Which function progesterone displays depends on the type of progesterone 
receptor and appears to be regulated by estrogen through multiple pathways based upon brain region.77  
    Another theory suggests that it is not estrogen nor progesterone providing glial protection, but rather 
testosterone that increases risk of glioma.  This is entirely plausible given that testosterone levels in women are 
approximately one tenth of the levels in men78 and growth of tumor cells are often promoted by testosterone, 
particularly in hormone dependent cancers.  In addition, testosterone has been shown to act directly via 
androgen receptors which are markedly more common in glial tumors than estrogen or progesterone receptors.53, 
54, 55, 56 But, like estrogen, testosterone can function as a neuroprotectant as well.  The neuroprotective effect of 
testosterone may be due to its conversion to estradiol by aromatase, as has been observed in cases of brain 
injury.79,80 Conversely, aromatase may promote tumor growth in the presence of tumor cells, as has been 
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demonstrated in glioblastoma cell lines.81 Whether glial risk is directly associated with testosterone or from 
mechanisms that occur after its conversion remains unclear.  Evidence correlating serum androgen levels to 
glioma incidence rates would bolster a theory of testosterone-derived carcinogenesis.  However, an appropriate 
surrogate is not apparent and there is little agreement to when testosterone levels drop among women.  Some 
report that levels of total serum testosterone remain unchanged across the menopausal transition, with a 
suggestion that there is a slight increase after menopause.82 Other studies observed a gradual decline starting 
after age thirty.90,83,84, 85   
    An increasing number of reports describe a high frequency of mitochondrial DNA alterations in 
glioblastomas.86,87,88 This has raised speculation to the role oxidative stress may play in gliomagenesis, 
particularly in light of the high rate of oxygen consumption by the brain.  Experimental and epidemiologic 
evidence have provided evidence supporting oxygen radicals as a risk factor in gliomas.  For example, Goldberg 
and colleagues demonstrated by scanning electron microscopy that free radicals injure C6 glioma cells.89 Cells 
have a variety of defenses against the harmful effects of oxygen radicals.  These include the enzymes 
superoxide dismutase (SOD), glutathione perioxidase, and antioxidants. Estrogen, a known natural antioxidant 
and initiator of SOD and glutathione perioxidase,90,91 is higher in females than males.  Thus, the female 
advantage in glioma risk may be due in part to a naturally higher level of antioxidants.  This theory is 
particularly tantalizing as it would explain the lack of estrogen receptor expression in gliomas since the 
antioxidant activity of estrogen is completely independent of estrogen receptor expression.   
    Despite the plausible mechanisms of hormonal protection described above, cytotoxic mechanisms of catechol 
estrogen metabolites may counter balance the neuroprotective effects exerted by estrogen and 2ME2.        
3.  Correlation between reproductive factors and hormones 
 
    Reproductive and menstrual factors are presumed to correlate with substantial hormone changes and 
influence lifetime levels of female hormone exposure.  However, studies have been unable to consistently 
demonstrate a correlation between endogenous sex hormones levels and reproductive factors.  No clear trends 
were observed when considering whether ovarian estrogens (premenopausal) or estrogens derived from 
aromatization (postmenopausal) differentially correlated with any of the reproductive factors, except in one 
study that found a positive association with age at menopause only shortly after menopause, not thereafter. 
Although pregnancies induce significant changes in hormone levels, there is little evidence of whether these are 
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the long term changes necessary to affect the latency required for cancer initiation.  Nearly all studies did not 
find a correlation between age at first birth and estrogen levels.92,93,94,95  Some found increases in estrogen levels 
with earlier age at menarche.101,96,97,98,99 while others found no association 102,104,100,101,102,103 even when accounting for 
lifetime estrogen exposure.104  
    Reasons for the demonstrated inconsistencies include the high variability in levels during different phases of 
the menstrual cycle not appreciated in single hormone measurements, poor reliability of some estrogen 
metabolites,105 or factors other than hormones that are more proximal determinants of reproductive factors.  For 
example, international studies found age at menarche was more closely related to a combination of extrinsic 
factors such as living conditions, diet, and physical work loads. Conversely, age at menopause was more 
sensitive to intrinsic parameters, such as reproductive history of individuals.106,107  The correlation between 
androgen levels and reproductive factors has to our knowledge not yet been studied.   
4.   Smoking and reproductive factors 
 
    Smoking has been shown to suppress estrogens while increasing levels of certain other sex hormones108,109 and 
is linked to impaired fertility and increased risk of miscarriage in women.110,111  The US Surgeon Generals report 
on smoking and womens health identified smoking as a cause of early menopause in women, on average two 
years earlier in smokers.112  Furthermore, smokers have been shown to have shorter menstrual cycles or a greater 
number of missed menstrual periods, on average, than non-smokers.113  Smoking related to gliomas is less 
convincing, but some findings assessing exposure levels and duration are suggestive of a correlation with 
gliomas.7, 114,115  
5. Previous epidemiologic studies of reproductive factors and gliomas 
 
    Results from epidemiologic studies investigating the association between reproductive and menstrual factors 
and gliomas have been somewhat contradictory. (Table 1.3)  
i) parity  
    Three of five case control studies found women having their first child were at reduced risk of gliomas 
compared with childless women (figure 1.2).  In the largest population based case control study to date (N=1657 
glioma cases), Lambe et al. reported a 24% reduced risk in ever parous Swedish women compared to 
nulliparous women (OR = 0.76 95% CI: 0.66-0.87).116  A more recent hospital based case control study of 212 
cases found similar, but non-significant, results (OR = 0.85 95% CI: 0.54  1.35).117 These findings differ from a 
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population-based study restricted to rural women in the upper Midwestern States (N=341 cases) which reported 
an elevated risk estimate (OR = 1.22 95% CI: 0.77-1.96) with ever giving birth and gliomas.128  Most, but not 
all, studies found that having more than number of children was protective only with higher order births (5+ 
children).  Likewise, being in a state of pregnancy not necessarily resulting in a live birth had little to no effect 
on glioma risk.126,118    
    We hypothesized in our study that ever having a child and ever being pregnant would decrease risk of 
gliomas.   
ii) age at fist birth  
 
    Earlier age at first birth may reduce the risk of gliomas. In a hospital based case control study, women who 
gave birth to their first child before 20 years were observed to have a significantly lower risk of glioma 
compared to nulliparous women (OR=0.43 95% CI: 0.23-0.83).167  Among women in Iowa, a nearly two fold 
excess glioma risk was reported by women giving birth between age range 25-29 as compared to women giving 
birth before age 20 (OR = 1.90, 95% CI: 1.00-3.60).119  Odds ratios did not increase with increasing age at first 
birth.  A similar lack of trend was observed in a larger population based case control study of Swedish 
women.125 Explanations are not readily apparent but patterns may simply reflect the protective effect of parity as 
women with more children typically start motherhood earlier or patterns may follow that of breast cancer where 
early age at first birth is thought to reduce the likelihood of tumor initiation while birth at a later age promotes 
the growth of existing tumor cells.120 
    We hypothesized in our study that later age at first birth would increase risk of gliomas. 
    iii) menopausal status  
 
    Two international studies analyzed menopausal status in relation to gliomas: one found no association 
comparing postmenopausal with premenopausal women (OR = 0.9 95% CI: 0.5-1.4).127 The other, a multi-center 
study, found postmenopausal women at significantly increased risk of gliomas (RR = 1.62 95% CI: 1.04-
2.51).121  Interpretation of these results may depend on the cutoffs used as different pathways may be involved. 
For example, estrogens present shortly after menopause predominantly reflect declining ovarian function.  
Estrogens present years after onset of menopause derive primarily from aromatization in fat tissue of androgens. 
If the determination of menopausal status is made at one year from last period, risk estimates may be 
underestimated given the large window of ovarian decline appreciated throughout perimenopause.    
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    We hypothesized in our study that postmenopausal women would be at increased risk of gliomas. 
    iv) age of menarche  
 
    McKinley found female incidence rates of gliomas among New York residents (1976-1995) diverged from 
male incidence rates around the time of menarche and converged again at menopause;6 however, this pattern is 
not readily apparent in the SEER data (1973-2000).  A hospital based case control study found women 
experiencing a later age at menarche were at nearly significant higher risk of glioma than their counterparts 
(≥14 years old vs  ≤11 years old: OR=1.92 95% CI: 1.08-3.39, p trend = 0.06).126 Similar results were found in 
the rural Upper Midwest Health Study, but only among postmenopausal women.131 (Table 1.4)  Odds ratios 
among postmenopausal women who had a later age at menarche were over 3 times that of younger age at 
menarche in relation to gliomas (<12 years old vs. 12-14 years old: OR= 0.48 95% CI: 0.22-1.01; >14 years old 
vs. 12-14 years old: OR = 1.62 95% CI: 0.86  3.05; p trend = 0.009).  Among premenopausal women, 
however, effect estimates hovered slightly below the null regardless of age at first period. (<12 years old vs 12-
14 years old: OR=0.91 95% CI: (0.49-1.68); >14 years old vs. 12-14 years old: OR=0.67 95% CI: (0.30-1.49). 
    We hypothesized in our study that a later age at menarche would decrease potential exposure to circulating 
hormones and increase risk of glioma. 
    v) age at menopause 
 
    The measurement of this event is inherently inexact due to individual variability in menstrual cycles and the 
perimenopausal transition.  Determining the age at menopause is more precise in women who underwent 
surgical procedures to remove both the uterus and both ovaries.  Variable definitions of age at menopause have 
been used in previous studies and most rely on recall.  Others improved on this measure attempting to account 
for the perimenopausal transition and defined it as the age at which menses had not occurred for at least 1 year.  
Of only two studies exploring age at menopause and glioma risk, both found no association with age at 
menopause (defined as age when menstrual periods stopped). 
    We hypothesized in our study that a later age at menopause would increase duration to circulating hormones 
and decrease risk of glioma. 
    vi) exogenous hormone use  
 
    All studies assessing exogenous hormone use and gliomas consistently reported risk estimates that fell below 
the null (figure 1.3).  A significant association between ever/never self reported use of exogenous hormones and 
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gliomas (RR = 0.65 95% CI: 0.44-0.96) was observed in a small subset of international women (N=59 cases).130 
With only 25% of rural women without tumors ever taking oral contraceptives,  the association with ever oral 
contraceptive use was less pronounced (OR = 0.83 95% CI: 0.58-1.20).  Hatch et al  reported an odds ratio of 
0.66 (95% CI: 0.44-1.00) with borderline significance in a study of urban women where prevalence of oral 
contraceptive use was 50% among controls.   Risk estimates for postmenopausal hormone use were also 
suggestive of a protective effect,  but  risks did not decrease with increasing duration of use, so findings may be 
spurious. (Table 1.5)     
    We hypothesized in our study that using exogenous hormones and using them for longer durations would 
decrease risk of glioma. 
    vii) cumulative exposure to endogenous female hormones  
 
    Lifetime exposure to endogenous sex hormones has been determined by several variables including timing of 
menarche, menstrual cycle regularity, age at first full term pregnancy, number of pregnancies, and age at 
menopause.  Cumulative exposure to endogenous female hormones is typically defined as the difference 
between age at menopause and menarche accounting for periods of marked hormonal changes such as occurs 
with pregnancy and breastfeeding. Results from the only study assessing cumulative exposure and gliomas 
observed decreasing odds ratios with increasing number of menstruation months among rural residents in the 
Midwest.131 
    In line with our hypothesis that hormones are neuroprotectants, we hypothesized in our study that greater 
cumulative exposure to endogenous female hormones would decrease risk of glioma. 
    viii) related reproductive factors  
 
    Breastfeeding is presumed to decrease estrogen exposure and delay the return of ovulation.  A single study 
found more glioma cases than controls with a history of longer breastfeeding duration, which agrees with our 
hypothesis.122  Other reproductive factors, however, support an association in the direction opposite than 
expected.  Miscarriages or abortions prevent a nearly 30 fold spike in estrogen produced toward the end of 
pregnancy in addition to a 10 fold increase in progesterone secretion throughout pregnancy.123 More controls 
than cases were found to have a history of miscarriage or induced abortion (OR = 0.82 95% CI: 0.59-1.15), with 
little attenuation when excluding proxies (OR = 0.72 95% CI: 0.48-1.08). 127  As these findings were from a 
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single study, it is difficult to speculate about the underlying mechanisms that would explain the diversity of 
estrogens effect.   
    Although not a reproductive factor, obesity is related to greater conversion of estrogens and thus may 
indirectly mediate the effects of hormones in brain cancers.  One study found an association between pre-
morbid body mass index and gliomas,124 but no other study has been conducted to substantiate findings.   
6.  Reasons for lack of agreement among previous studies 
 
    What we know of hormones and brain tumors comes from self-report measures of menstrual activity, 
reproductive events, and exogenous hormone use.  The results of studies using surrogate measures have been 
inconsistent and, at times, contradictory.  Reasons for this could be due to recall bias which could move the 
effect estimate either away or towards the null. It is not expected that women have poor recall of sentinel events 
such as having a child, maternal age at first birth, or menarcheal age.  Rather, the large number of proxy 
respondents which is unavoidable in case control studies of fatal cancers is likely to account for the majority of 
exposure misclassification. Agreement between proxy and case reported information has been shown to be 
reliable with parity but unreliable for other reproductive factors.125,126,127 Of the three previous studies stratifying 
analyses by proxy status, similar results were observed when excluding and including proxies.126,127,131 
    Another reason for lack of agreement between studies is lack of a standard definition of a very heterogeneous 
group of tumors.  Histologic subcategorization of gliomas by ICD-O codes has aided in minimizing disease 
heterogeneity but potential problems still exist as histologic features between subtypes often overlap and thus 
are left to the subjective interpretation of the pathologist which appears to vary depending on when or where 
pathologist(s) were trained.  In addition, there has been a revision of codes over time due to advancements in 
molecular biology and the discovery of more robust classifiers of brain tumor subtypes. Previous studies 
included subtypes that were lacking in another study ultimately limiting comparability between studies. (Table 
1.6)  As each subtype is believed to derive from different etiologies and courses of progression, lumping them 
together into one category is likely to attenuate effect estimates.  For those few studies utilizing histologic 
information of tumor subtypes, stratified case numbers were small limiting statistical power to detect weak 
effects.  
    Differences in control selection must be considered as they can impact effect estimates.  For example, two of 
eight previous studies investigating reproductive factors and gliomas were hospital based case control studies.  
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Hochberg et al. selected controls from friends.128 Selection of controls from friends has an inherent disadvantage 
as they may be related to cases by similar exposures.  Hatch et al. selected controls from hospitalized patients 
with a variety of conditions other than brain tumors.126  Hospital based controls may be underepresentative of 
the exposure distribution in the source population.  These concerns were addressed by assessing whether the 
results were sensitive to specific diagnoses included in the controls group.  While effect estimates from these 
two studies found similar effect estimates in regards to age at menarche, a 1.5 fold difference in age at 
menarche was noted in premenopausal women compared with Huang et al. most recent population based study 
of rural women131 (crude numbers used to create similar reference group).   Other reproductive variables did not 
demonstrate such a dichotomy indicating that study design and control selection cannot fully explain differences 
of effect estimates.   
    A challenge to epidemiologic studies of cancer, and more so rare cancers such as gliomas, is the relatively 
small numbers of cases available.  Reproductive factors may have a true weak effect on glioma risk, but may be 
lost in random variations if the sample size is too small.     
7.  Summary 
 
    Despite these methodological problems, the characteristic gender predisposition of brain tumors displayed 
across virtually all types of human subpopulations strongly suggests that there may be a hormonal influence on 
brain tumors.  Supporting this hypothesis are findings of hormone receptors in gliomas; correlation between 
malignancy grade in gliomas and presence of hormone binding;47,129  higher growth advantage in human male 
glial tumors compared to human female glial tumors implanted in nude mice;32 incidence of malignant gliomas 
lower in pregnancy when compared to nonpregnant women of similar age;130,131 and a decrease in protection after 
menopause.  Perhaps more intriguing are recent findings that age at menarche and menopause are points of 
change in glioma incidence rates 6 and greater months of menstrual cycling impart more protection against 
glioma risk.126    
E.  Manuscript 2:  DNA repair polymorphisms XRCC1 Arg399Gln, MGMT Leu84Phe, and MGMT 
Ile143Val and gliomas 
 
1. DNA repair and carcinogenesis 
 
    A primary mechanism of carcinogenesis is the process of acquiring DNA mutations to several critical genes 
controlling tightly regulated cell cycle activities.  These mutations are mainly caused by exogenous (e.g., 
smoking, radiation, chemicals, drugs) and endogenous (e.g., free radicals, products of normal metabolism) 
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exposures.  Normally, DNA repair genes maintain constant vigilance repairing damage caused by mutations 
through multiple DNA repair pathways, including direct reversal repair, base excision repair (BER), nucleotide 
excision repair (NER), mismatch repair (MMR), and double strand break repair.  Mutations to DNA repair 
genes in these pathways may compromise the cells ability to repair and, in turn, modulate individual cancer 
susceptibility.132 Studies have reported a link between DNA repair polymorphisms and several cancers,133 but 
data evaluating repair polymorphisms in gliomas is limited.   
2. XRCC1 polymorphism Arg399Gln 
 
    X-ray repair cross complementing group 1 (XRCC1) is a critical component of the base excision repair 
pathway. XRCC1 codes for a protein that interacts with other BER proteins to recognize, remove, and refill 
base damage and DNA single strand breaks caused by endogenous and exogenous toxic agents.134  More 
specifically, glycosylases initiate incision to damaged DNA leaving a gap to which XRCC1 binds.  XRCC1 
inserts DNA polymerase B in the gap to start synthesizing new DNA.  Finally, XRCC1 signals DNA ligase III 
to seal the gap.  XRCC1 protein has been constitutively expressed in the entire mouse brain.135  Rodents lacking 
XRCC1 are hypersensitive to an extensive number of genotoxins, exhibit genetic instability, and may be 
embryonic lethal.  These findings suggest XRCC1 plays an essential role in removing endogenous and 
exogenous DNA damage to brain tissue.   
    The XRCC1 gene is composed of 633 amino acids and is located on chromosome 19q13.2-3.136 Alterations of 
chromosome 19 has been observed in all three major types of gliomas, 40% of gliomas137,138 and over 80% in 
oligodendrogliomas139,140,141,142,143 suggesting the importance of this gene region to gliomagenesis.  The 
polymorphism of interest in this study involves a nonconservative amino acid change (arginine to glutamine) at 
an evolutionarily conserved region of XRCC1 at codon 399 in exon 10.   Codon 399 is located in the 
poly(ADP-ribose) polymerase-binding regions (PARP) and within the BRCA1 COOH terminus domain.144,145  
The prevalence of the XRCC1 399 variant among Caucasians has been estimated around 35%.  Although the 
function of XRCC1 variant alleles is unknown, rodent studies have demonstrated alteration of XRCC1 function 
where DNA repair capacity was significantly impaired.146 In the sentinel study by Lunn and colleagues, the 
399Gln allele was associated with increased aflatoxin DNA adducts in placental tissue and somatic glycophorin 
A variants in erythrocytes.147 Duell and colleagues reported increased levels of DNA adducts from blood 
mononuclear cells, as well as sister chromatid exchange frequencies in lymphocytes from smokers.148  Other 
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studies demonstrated the effect of the 399Gln allele on chromosomal aberrations was significantly modified by 
smoking.149,150,151  Epidemiologic studies of cancer risk in relation to the XRCC1 Arg399Gln polymorphism has 
been largely inconsistent with the majority of studies finding increased risk for lung, colorectal, and breast 
cancer, but decreased risk with bladder, head and neck, and skin cancer. (Table 1.7)  Gliomas were recently 
investigated in a hospital based case control study in relation to XRCC1, XRCC3, and XRCC7 polymorphisms 
(N=309 ).152 (Table 1.8)  Only XRCC7 variants were found to be statistically significant.  Although the 399Gln 
variant has not been directly associated with gliomas, it is known to interact with other base excision repair 
enzymes such as apurinic/apyrimidinic endonuclease 1 (APE1) 153,154,155,156  whose activity has been shown to 
increase in adult gliomas.157 
3.  MGMT polymorphisms Leu84Phe and Ile143Val 
 
    O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that protects cells primarily 
from alkylating agents, but also is induced by ionizing radiation, ultraviolet radiation, and hormones.158,159,160   
Once induced, MGMT directly and specifically removes alkyl DNA adducts at the O6 position of guanine by 
transferring the alkyl group to one of its own cysteine residues thus preventing a G:C to A:T transition.  MGMT 
is expressed in all human tissues, although levels and activity vary significantly among tissue types.  Esteller 
reported in their study that 92% of glial tumors that lack MGMT expression showed MGMT promoter 
hypermethylations, whereas 94% tumors that retained expression of MGMT were unmethylated at the MGMT 
CpG islands.161  The highest frequencies of aberrant MGMT methylation in Bellos series of 469 nervous system 
tumors occured in gliomas, primarily in anaplastic subtypes and GBM,162 while another study found 
hypermethylation of MGMT occurred more frequently in oligodendrogliomas than astrocytic tumors for 
MGMT (80% vs 59%).163  Low levels of MGMT are generally a predisposing factor for tumorigenesis in human.  
Loss of MGMT is most frequently due to epigenetic changes, especially hypermethylation of its promoter 
region.   
    MGMT is located in chromosome 10q26 where heterozygous deletion is often observed in GBM patients.  
The functional significance of MGMT polymorphisms is largely unknown, but a previously published MGMT 
enhancer polymorphism (1099C → T) forming a haplotype with codon 84 demonstrated increased reporter gene 
activity.164  A recent study of healthy volunteers found significantly higher levels of chromosome aberrations 
induced by tobacco-specific carcinogen NNK among carriers of MGMT polymorphisms.165  Several 
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polymorphisms of MGMT have been described but only a few found statistically significant associations with 
lung cancer. (Tables 1.9, 1.10)  Of interest in this study are the C>T transitions causing a single amino acid 
change at codon 84 (Leu84Phe) and at codon 143 (Ile143Val).  Polymorphisms at codon 84 are missense 
mutations located in exon 3.  The 84 variant has similar activity as the wildtype protein and appears to have 
similar frequency in ethically distinct populations.166 Ma et al. found no defect MGMT function with 
polymorphisms at codon 84 in Swedish, Japanese, Chinese, and other Caucasian populations.167   Li et al. found 
no independent association with bladder cancer, but statistically significant risk estimates were reported when 
the Leu84Phe polymorphism was analyzed jointly with the silent polymorphism Leu53Leu.168  The Leu84Phe 
polymorphism has been associated with gliomas, but study sizes were small. (Table 1.11)  Of 22 GBM cases 
among Asians, the odds ratio for the combined heterozygote variant and wild type MGMT was 2.91 (1.19-
7.08).169  Polymorphisms at codon 143 are also missense mutations but located in exon 5, next to the alkyl 
acceptor Cys 145 of the MGMT active site.  Unlike variants at codon 84, the Ile143Val variant demonstrates 
significant ethnic differences in its distribution.  To our knowledge, no study has been conducted investigating 
the Ile143Val polymorphism in relation to brain tumors.      
4.  ERCC1 polymorphism C8092A 
 
    Excision repair cross-complementing group 1 (ERCC1) is an essential component of the NER pathway.  This 
repair gene works in complex with ERCC4 (XPF) to form a structure-specific endonuclease critical to the dual 
incision step of nucleotide excision repair.  Their function is to introduce breaks into double stranded DNA to 
fix alterations caused by genotoxins such as ionizing radiation and smoking.170,171,172  Mutations in ERCC1 are not 
known to be associated with any human disorder, but knockout mice were embryonic lethals.173  The functional 
significance of ERCC1 is not yet known, but ERCC1 polymorphisms have been suggested to be associated with 
ERCC1 mRNA levels and DNA repair capacity.174 The ERCC1 C8092A polymorphism was found to 
specifically overlap with the 3end of another gene, ASE-1. 175 There is speculation that the ERCC1 silent 
polymorphism could indirectly affect transcription by interacting with the coding region of ASE-1.  
    ERCC1 variants at codon 8092 have been assessed in glioma, head and neck, and lung cancers.  There was a 
significant association in a small subset (n=28) of oligoastrocytomas (OR = 4.4 95% CI: 1.6-12.2). 10 An 
extension of this study enrolling more participants (n=450 cases) found no overall association of ERCC1 
genotypes with glioma, although there was a suggestive increased odds ratio for AA vs AC/CC genotypes 
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among GBM cases (OR=1.67 95%CI: 0.93-3.02).176  The discrepancy in results is likely due to the larger sample 
size. No meaningful association was reported in lung (OR=1.26 95% CI: 0.81-1.96) or head and neck cancers 
(OR=1.15 95% CI: 0.84-1.59), but effect estimates were significantly modified by cumulative smoking 
exposure.  
5. ERCC2 polymorphisms Arg156Arg and Lys751Gln 
 
    Excision repair cross-complementing group 2 (ERCC2 or XPD), is located within the same chromosomal 
19q13.2-13.3 region as ERCC1 and XRCC1 and in close proximity to the putative glioma suppressor genes 
(GLTSCR1 and GLTSCR2). ERCC2 encodes the helicase essential to unwinding damaged DNA and triggering 
the incision and excision of damaged nucleotides in the NER pathway.  ERCC2 is an essential protein for cell 
viability,177 thus no person can have two null alleles.  Mutations in ERCC2 may lead to deficient repair of DNA 
lesions,178 but their functional significance remains unknown.  Several common single base pair substitution 
polymorphisms in the ERCC2 gene have been identified.  The polymorphisms most frequently associated with 
cancers include a silent polymorphism at codon 156, and polymorphisms resulting in amino acid changes at 
codons 312 (aspartic acid to asparagines) and 751 (lysine to glutamine).  Associations with lung, skin, bladder, 
esophageal, colorectal, and head and neck cancers have been largely inconsistent, perhaps due to small sample 
sizes and varying assay types.  In relation to brain tumors, alterations of ERCC2 copies were observed in 
malignant brain tumors compared to nonmalignant brain tumors.183,179   
    Of interest in this study are ERCC2 variants Arg156Arg and Lys751Gln.  Both alleles were chosen because 
their allele frequencies are higher (≥25%)13 than other ERCC2 variants and have been previously implicated in 
gliomas.11  Functional studies assessing the affect of these ERCC2 polymorphisms on DNA repair have been 
limited to small sample sizes with conflicting results.  Lunn and colleagues reported that individuals with the 
more common polymorphic variant (Lys751Lys) had more chromosome aberrations and consequently a 7-fold 
increased risk of suboptimal DNA repair when exposed to X-rays than those with the 751Gln variant in a small 
study of breast cancer patients.180  Spitz found the reduction in repair capacity among lung cancer patients was 
greater in homozygous variant (Gln751Gln) than wild type homozygotes exposed to BPDE.181  Conversely, 
Affatato et al. failed to find significantly increased chromosome aberrations when using a tobacco specific 
mutagen.182  Qiao et al. reported diminished repair capacity for UV-induced DNA damage in homozygote 
variants (Gln751Gln) versus homozygous wild type.183  Functional studies of the silent variant at codon 156 
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demonstrated higher chromosome breaks after UVC irradiation in the lymphocytes of psoriasis patients.184  In a 
sample of healthy subjects, only the homozygous variant (Arg156Arg) was associated with lower repair 
capacity after exposure to UV.  No overall association was found in all studies of lung cancer unless ERCC2 
variants at codons 751 and 312 were considered jointly.185,186 One study of head and neck cancer reported 
slightly higher risk with the Lys751Gln variant (OR = 1.7 95% CI: 1.0-2.8).187  
6. Smoking as a risk factor: gene-environment interaction 
 
    Because we are considering low penetrant genes, they may require an interaction with one or more 
environmental factors.  Assessment would ideally require a strong and consistent environmental risk factor of 
gliomas, such as ionizing radiation.  The parent study did collect data on radiation exposure, but a preliminary 
cumulative exposure classification scheme has not yet been developed.  Therefore, we used smoking exposure 
to assess a repair gene-environment interaction for the following reasons. 
    Smoke contains compounds (e.g. benzene, aromatic amines, and PAHs) that have indisputably been found to 
induce tumors188 and generate reactive oxygen species (ROS) capable of inducing double strand breaks in 
DNA.189, 190   The brain is an oxygen rich organ inherently sensitive to ROS.  Experimental and epidemiologic 
evidence have provided evidence supporting oxygen radicals as a risk factor in gliomas. 191,192,193 However, 
epidemiologic studies have failed to find a consistent association between gliomas and smoking.  Plausible 
reasons could be that the blood brain barrier is an efficient protective mechanism denying access to most 
carcinogenic components of tobacco smoke as PAHs are capable of producing damage to neural cells only at 
very high concentrations.194 However, results do not account for those tobacco-related genotoxins which can 
either bypass the BBB (e.g. via the intranasal pathway) or may otherwise penetrate the BBB (e.g. N-nitroso 
compounds, another constituent of tobacco smoke).   Brain specific enzymes responsible for metabolizing 
carcinogens may efficiently break down these compounds into less toxic substances.  Molecular studies support 
this theory as some GST variants are 4 fold more prevalent in malignant gliomas than normal brain tissue. 195  
However, epidemiologic studies have more varied findings.  De Roos and colleagues demonstrated an 80% 
increased risk of glioma with GSTP1 variants,80 while Wrensch196  and Pinarbasi197 found little evidence to 
support associations between GST variants and gliomas.  
    Seventeen studies (2 retrospective cohorts, 5 hospital based case control studies, 9 population based case 
control studies, 1 case control study with population based and hospital based control selection) have 
 20
investigated tobacco smoking and risk of gliomas.  Results varied across studies with risk estimates ranging 
from 0.6 to 1.6 for ever/never smoking (figure 1.4).  In two of the largest studies (n=416 cases, n = 434 cases 
respectively), odds ratios were notably higher among male smokers than female smokers.124,198  Of the ten studies 
considering quantities smoked, only one case control study demonstrated a dose-response relationship of 
smoking unfiltered cigarettes (trend p=0.026).199  The only cohort performed to date suggests a modestly 
increased risk for gliomas among female smokers with increasing exposure levels (trend p = 0.04).7  However, 
with only 55 female cases and 75 male cases, estimates are unstable and confidence intervals imprecise for any 
firm conclusions (female RR = 3.0 95% CI: 0.9-10.6; male RR = 1.9 95% CI: 0.9-4.2; both in highest exposure 
levels).  Inconsistencies between studies are likely due to differing definitions of ever smoking and 
heterogeneity in methods determining length of smoking.  For instance, some defined ever smokers as those 
who smoked any time for any duration or any amount during lifetime, others required smoking at least once a 
day for 3 months, smoked continuously for one year during life, or smoked at least five years prior to diagnosis.  
Similarly, never was defined in some studies as never using a tobacco product during life, others relaxed the 
definition and included subjects smoking less than 100 cigarettes during lifetime into the never smoker 
category.  Levels of exposure were typically assessed by pack-years, cigarette years, and/or cigarettes per day.  
High levels of exposure included various cutpoints for categorization, ranging from greater than 25 to greater 
than 49 pack years.  Despite differing cutpoints, the highest categories of smoking exposure were associated 
with the lowest risk estimates in the majority of studies.200,201,202,203 Hospital based case control studies generally 
demonstrated higher risk estimates with smoking exposure, but smoking variables were limited to dichotomous 
exposures and case numbers for these studies were among the lowest.  With six of the seventeen studies having 
less than 100 participating cases, most investigators combined glioma subtypes for analysis of smoking 
exposures.  Considering these issues, it is difficult to conclude whether smoking is related to glioma risk.  
Overall, the data do not appear to support any important associations, but there remains notable findings in the 
larger cohort and case control studies that may suggest an influence of smoking in gliomagenesis.   
    A review of studies assessing XRCC1 polymorphisms and cancer risk in Asian populations reported that 
while XRCC1 polymorphisms are weakly associated with cancer, when combined with smoking, these 
polymorphisms demonstrate a three fold increase in the risk of cancer.204 Regardless of cancer type, the majority 
of studies was suggestive, if not strongly associated, with the 399Gln variant being modified by smoking.  
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Interestingly, most found the joint effect to be important only in persons with never or lower degrees of 
cigarette use. 205,206,207,208 Only one study reported increased risk with increased duration of smoking among 
399Gln alleles in a population based study of pancreatic cancer.209 Two studies of breast and bladder cancer 
observed elevated risk estimates for duration of smoking when considering the homozygous referent.210,211  Of the 
few studies evaluating the interaction between MGMT polymorphisms and smoking,  the MGMT 84 variant 
was found to modulate the association between cigarette smoking and breast cancer,212 but not gastric cancer213 
nor head and neck cancer.214 
7.  Gene-gene interactions between XRCC1/ERCC1/ERCC2 polymorphisms 
 
    Recent studies suggest polymorphic repair genes may not act alone, but may amplify the effect of a mutation 
in another repair pathway.  Additive or multiplicative effects of combined genetic variants for different DNA-
repair pathways have been previously reported for lung cancer, melanoma, prostate, and breast cancer.  With 
repair genes ERCC1 and ERCC2 previously associated with gliomas residing in the same chromosome region 
(chromosome 19q13.2-3), it is plausible that multiple polymorphisms within the same pathway increase cancer 
risk. The true effect, however, may be masked by linkage disequilibrium with another nearby gene in another 
repair pathway such as XRCC1.  Because DNA damage may involve repair from both BER and NER pathways, 
finding whether there is a beneficial effect with both pathways as compared to one will provide substantial 
knowledge to DNA repair mechanisms in gliomagenesis.   
8.  Previous epidemiologic studies of DNA repair polymorphisms and gliomas 
 
    Only four studies have previously evaluated polymorphisms of DNA repair genes and glioma risk.  Three of 
these studies drew cases and controls from the San Francisco Bay Area Adult Glioma Study to investigate 
polymorphisms of DNA repair genes ERCC1 and ERCC2.  Chen and colleagues in a population based case 
control analysis (122 cases and 159 controls) observed that individuals with the CC variant of ERCC1 
polymorphism 8092 were associated with a large increased risk (OR=4.4; 95% CI = 1.6-12.2) among 
oligoastrocytomas.10 Such large risk estimates are not typically expected in cancer studies and are likely the 
result of the small number of cases (n=28) as demonstrated by the wide confidence intervals.  Individuals with 
astrocytoma also had elevated odds (CC vs. AA/AC: OR=1.6; 95% CI: 0.7-3.5), but no association was 
observed for glioblastoma multiforme cases (CC vs. AA/AC: OR=0.9; 95% CI=0.5-1.6).  Once again, case 
numbers are too small to arrive at a definite conclusion (32 cases and 62 cases, respectively). Given these 
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positive results and the close proximity ERCC1 has with ERCC2 in the 19q region, Caggana and colleagues 
went further to explore whether polymorphisms in ERCC2 would impact glioma risk using the second series of 
the San Francisco Glioma Study.11 Carriers of the variant Arg156Arg demonstrated a significantly increased 
glioma risk, regardless of histologic type (OR = 2.3 95% CI: 1.3-4.2), but were less likely to carry the 
Lys751Gln variant.  This study, too, was hampered by small sample size, particularly when stratified by tumor 
type.  Combining both series to increase sample size, Wrensch and colleagues did not observe a significant 
independent effects of ERCC1 or ERCC2, but cases were significantly more likely to have two variant alleles at 
both ERCC1 and ERCC2 at codon 751.185  
    To our knowledge only one study has examined the relationship between XRCC1 DNA repair genotypes and 
risk of glioma.161  In this hospital based case control study of 309 glioma cases, the frequency alleles of the 
XRCC1 variant (Arg399Gln) was not statistically different between cases and controls. (Table 1.8)     
    Several epidemiologic studies have investigated promoter hypermethylation of MGMT in gliomas, but only 
one examined polymorphic MGMT in primary brain tumors.  Frequencies of MGMT genotypes among Asians 
were not different between primary brain tumors patients as an aggregate and healthy controls.  However, 
among patients with primary glioblastomas (n=22, table 1.11), the combined heterozygote (Leu/Leu or 
Leu/Phe) were significantly higher in cases than controls (OR=2.91 95% CI: 1.19-7.08).178    
 9.  Summary 
 
    DNA repair genes are critical in protecting cells from the consequences of potentially toxic environmental 
exposures humans receive on a daily basis.  Repair gene variants with impaired function are known to increase 
cancer susceptibility.  As no compelling leads exist at this time to suggest common environmental exposures 
contribute to the majority of glioma cases, we may conclude the repair mechanisms in the nervous system are 
highly efficient, and/or genetic events interact with environmental exposures to affect susceptibility as is 
common with many other cancers.  This study presents an opportunity to clarify how genetic and environmental 
factors affect DNA repair and contribute to glioma susceptibility.     
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F. Figures and tables 
 
1.  Figures and tables for Introduction 
 
 
Figure 1.1:  Glioma incidence rates by 5 year age groups and proportionally by gender, 1973-2000. CBTRUS 
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Table 1.1: Incidence ratesa , survival rates, and age distribution of gliomas by histologic types,  
age-adjusted to the 2000 U.S. Standard Population, CBTRUS 1997-2001 
 
Incidence 
Rate 
Histology 
By Gender 
Female:Male 
Incidence Rate 
Ratio 
5 yr Relative 
Survival Rate 
Median Age 
At 
Diagnosis 
0.32 Pilocytic  
Astrocytoma Male: 0.33 
Female: 0.31 
0.94 90.8 12 
0.10 Diffuse  
Astrocytoma Male: 0.12 
Female: 0.08 
0.67 46.9 45 
0.47 Anaplastic 
Astrocytoma Male: 0.56 
Female: 0.40 
0.71 29.7 51 
0.47 Astrocytoma, 
NOS Male: 0.56 
Female: 0.39 
0.70 36.9 46 
3.01 Glioblastoma 
Male: 3.75 
Female: 2.40 
0.64 3.4 64 
0.37 Oligodendroglioma 
Male: 0.40 
Female: 0.34 
0.85 69.6 41 
0.17 Anaplastic 
Oligodendroglioma Male: 0.19 
Female: 0.16 
0.84 41.9 48 
0.25 Ependymoma/ 
Anaplastic ependymoma Male: 0.29 
Female: 0.22 
0.76 69.7 39 
0.15 Mixed glioma 
Male: 0.17 
Female: 0.13 
0.76 55.9 42 
0.38 Malignant glioma, 
NOS Male: 0.41 
Female: 0.35 
0.85 30.0 46 
 ARates are per 100,000 person-years. 
Abbreviations: CBTRUS: Central Brain Tumor Registry of the United States;NOS: not otherwise specified 
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Table 1.2: Risk factors investigated in relation to gliomas 
 
 
 
 
 
 
 
 
 
  
*created from reviews of brain tumor risk factors, Inskip8 and Wrensch215 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Established factors associated with gliomas
High dose ionizing radiation 
Genetic syndromes (neurofibromatosis, tuberous sclerosis, Turcot syndrome, Li-
Fraumeni syndrome) 
 
Likely factors associated with gliomas 
 Dietary exposure to N-nitroso compounds 
 Occupational solvent exposure 
 Allergies and autoimmune disease 
 Viruses 
 Sex hormones 
 
Possible factors associated with gliomas  
 Head trauma 
 Smoking 
 NSAIDs 
 Radiation 
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2.  Figures and tables for Manuscript 1 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2:  Previous odds ratios of ever giving birth and gliomas
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  *HRT = hormone replacement therapy; OC = oral contraceptive use; NS = not specified 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Previous odds ratios of ever exogenous hormone use and gliomas
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Table 1.3:  Epidemiologic studies of reproductive factors and gliomas 
Reproductive  Variable   Adjusted OR  Author   
Factor   Categorization  (95% CI)     
Parity   Ever/never  0.85 (0.54-1.35)  Hatch 2005 
      1.22 (0.77-1.96)  Huang 2004 
      0.76 (0.66-0.87)  Lambe 1997 
      0.44 (0.30-0.70)  Cantor 1993   
NR   Ryan 1992 
 
Gravidity  Ever/never  0.89 (0.54-1.47)  Hatch 2005  
      NR   Schlehofer 1999  
      1.10 (0.60-2.10)  Cicuttini 1997 
 
Number of children 1   0.97 (0.54-1.75)  Hatch 2005 
   2   0.85 (0.50-1.44) 
   3   0.90 (0.49-1.65) 
   4   0.91 (0.47-1.79) 
   5+   0.45 (0.21-0.99) 
1   0.77 (0.66-0.92)   Lambe 1997         
   2   0.73 (0.62-0.85) 
   3   0.80 (0.66-0.96) 
   4   0.76 (0.58-1.01) 
   5+   0.62 (0.42-0.92)*  
    
2   0.90 (0.50-1.80)   Cantor 1993 
   3   0.60 (0.30-1.30) 
   4   1.20 (0.60-2.40) 
   5+   1.20 (0.60-2.40) 
Age at first birth  < 20 yoa   0.43 (0.23-0.83)  Hatch 2005 
20-24 0.89 (0.53-1.50) 
25-29 1.24 (0.69-2.23) 
30+   1.04 (0.52-2.07)* 
20-24 yoa    0.85 (0.58-1.24)  Huang 2004 
   >25   0.97 (0.60-1.57) 
   20-24 yoa  1.02 (0.84-1.24)  Lambe 1997 
   25-29   1.05 (0.85-1.30) 
   >=30    0.99 (0.76-1.28) 
    
20-24 yoa  1.30 (0.70-2.20)  Cantor 1993 
   25-29   1.90 (1.00-3.60)     
   >=30   1.30 (0.60-3.00) 
 
Age at menarche  12-13 yoa  1.69 (1.01-2.83)  Hatch 2005 
   >=14    1.90 (1.09-3.32) 
>14 yoa/<14 yoa  2.10 (0.90-4.90)  Hochberg 1990 
 
Age at menopause 40-44 yoa  0.68 (0.31-1.51)  Hatch 2005 
45-49 0.92 (0.43-2.00) 
50+   1.53 (0.76-3.05) 
>50 yoa/<=50 yoa 1.07 (0.55-2.11)  Huang 2004 
Menopausal status Post/pre   0.85 (0.48-1.50)  Hatch 2005 
1.62 (1.04-2.51)  Schlehofer 1999 
      0.90 (0.50-1.40)  Cicuttini 1997 
* p trend < 0.05 
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Table 1.4:  Epidemiologic studies of reproductive factors and gliomas by menopausal status 
 
Reproductive  Variable  Premenopausal  Postmenopausal Author 
Factor   Categorization OR (95% CI)  OR (95% CI) 
 
Age at menarche  <11  1.00   1.00  Hatch 2005 
   12-13  1.53 (0.68-3.47)  1.65 (0.83-3.31) 
   14+  2.10 (0.86-5.15)  1.68 (0.81-3.48) 
   
   <12  0.91 (0.49-1.68)  0.48 (0.22-1.01) Huang 2004 
  12-14  1.00   1.00 
  >14  0.67 (0.39-1.49)  1.62 (0.86-3.05) 
 
Age at first birth  Nulliparous 1.00   1.00  Hatch 2005 
<20  0.40 (0.15-1.08)  0.44 (0.18-1.10) 
   20-24  1.12 (0.53-2.37)  0.66 (0.31-1.41) 
   25-29  3.26 (1.32-8.05)  0.69 (0.30-1.59) 
   30+  1.26 (0.45-3.59)  0.79 (0.30-2.10) 
 
Parity   No  1.00   1.00  Hatch 2005 
   Yes  1.13 (0.61-2.08)  0.65 (0.32-1.30) 
 
Number of births  None  1.00   1.00  Hatch 2005 
   1  1.14 (0.50-2.60)  0.77 (0.32-1.87) 
   2  1.09 (0.53-2.26)  0.71 (0.32-1.58) 
   3 or more 1.17 (0.53-2.60)  0.57 (0.27-1.21) 
 
Gravidity  No  1.00   1.00  Hatch 2005 
   Yes  1.29 (0.66-2.52)  0.53 (0.25-1.15) 
 
Number of pregnancies None  1.00   1.00  Hatch 2005 
   1-2  1.37 (0.66-2.85)  0.59 (0.25-1.37) 
   3  1.65 (0.70-3.87)  0.54 (0.22-1.31) 
   4 or more 0.88 (0.37-2.11)  0.48 (0.21-1.10) 
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Table 1.5:  Epidemiologic studies of exogenous hormone use and gliomas  
 
Reproductive  Variable   OR   Author   
Factor   Categorization  (95% CI) 
     
 
OC use   Ever/never  0.66 (0.44-1.00)  Hatch 2005 
0.83 (0.58-1.20)  Huang 2004 
  
OC use duration  Never   1.00   Hatch 2005 
   <1 yr   0.69 (0.37-1.31) 
   1-4    0.68 (0.41-1.12) 
   5-9    0.40 (0.20-0.79) 
   10+   0.85 (0.45-1.59) 
        p trend = 0.57 
      
   >5 yrs/<=5 yrs  1.02 (0.53-1.95)  Huang 2004 
 
   
HRT use  Ever/never  0.66 (0.41-1.09)  Hatch 2005 
0.73 (0.49-1.10)  Huang 2004 
 
HRT use duration Never   1.00   Hatch 2005 
   <1 yr   0.61 (0.24-1.54) 
1-4 0.62 (0.29-1.34) 
5-9 0.55 (0.22-1.34) 
10+   0.86 (0.43-1.72) 
     p trend = 0.30 
    
   >5 yrs/<=5 yrs  0.88 (0.42-1.83)  Huang 2004 
 
Exogenous hormone use NS   0.65 (0.44-0.96)  Schlehofer 1999 
        
 
 
Abbreviations: OC=oral contraceptives; HRT=postmenopausal hormone replacement therapy, NS=not specified 
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3.  Figures and tables for Manuscript 2 
 
 
Figure 1.4: Previous odds ratios of ever smoking and gliomas
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Table 1.8  Results from previous study investigating  
XRCC1 Arg399Gln polymorphism and gliomas 
. 
Wang L. and Bondy M. (2004)   
 
       Cases               Controls   
XRCC1 Arg399Gln   (n=309)        (n=342) 
Polymorphism   
No.   (%)  No.   (%)     OR (95% CI)ω  P* 
   
 
  
Arg/Arg   134 (43.4)  131 (38.3)      1.00 
Arg/Gln   138 (44.7)  162 (47.4)      0.83 (0.60-1.16) 
Gln/Gln     37 (12.0)    49 (14.3)      0.74 (0.45-1.21) 
Arg/Gln + Gln/Gln 75 (56.6)  211 (61.7)      0.81 (0.59-1.11)          0.189 
Gln allele frequency       0.343        0.380               0.184 
 
*two sided chi-squared test 
ωcalculated from raw data 
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Table 1.11: Results from previous study investigating 
 MGMT Leu84Phe polymorphism and gliomas 
 
Inoue R. Isono M et al. (2003) 
 
        Cases             Controls   
MGMT Leu84Phe      (n=58)              (n=225) 
Polymorphism    
No.   (%)  No.   (%)     OR (95% CI)   
 
Glioblastoma:  
Leu/Leu     11 (50)  160      (38)      1.00 
Leu/Phe     11 (50)    55      (47)      2.91 (1.19-7.08) 
Phe/Phe       0 (  0)      9      (14)       
Total     22   225   
 
Gliomas: 
 Leu/Leu     43 (75)  160      (38)      1.00 
 Leu/Phe     14 (25)    55      (47)      0.95 (0.48-1.86) 
 Phe/Phe       0 (  0)      9      (14) 
 Total     57   225 
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CHAPTER II:  STUDY DESIGN AND METHODS 
 
A. Conceptual hypothesis and specific aims for Manuscript 1- Reproductive factors and hormone use and risk 
of gliomas among females 
 
    The most consistent finding in relation to glioma risk is the higher incidence in males compared to females 
across all subpopulations.  The female advantage may be due, in part, to endogenous female hormones which 
are ubiquitous to women and irrelevant to the blood brain barrier.  Female hormones have diverse effects in the 
central nervous system, including neuroprotection. (Figure 2.1)  Life events which substantially change the 
female hormonal milieu will affect individual susceptibility to gliomas among women.  Earlier age at menarche 
and later age at menopause lengthen the reproductive period which is thought to result in either increased levels 
of female hormones over time or a longer duration of average female hormone exposure.  We hypothesized 
that greater potential exposure to female hormones will decrease risk of adult onset gliomas. The specific aims 
of this study include the following: 
Aim 1:  To determine risk of adult onset gliomas among women in the San Francisco Bay Area 
associated with surrogates of female hormone exposure to include reproductive history factors (age at 
first birth, gravidity, parity, number of children), menstrual history factors (age at menopause, age at 
menarche, menopausal status, type of menopause), exogenous hormone use (oral contraceptive and 
postmenopausal hormone replacement therapy), and cumulative female hormone exposure (age at 
menarche, age at menopause, postmenopausal hormone duration) 
Aim 2:  To determine whether risk estimated by reproductive, menstrual, and exogenous hormonal 
exposures differs by age, race, and tumor subtype 
Conceptual hypothesis and specific aims for Manuscript 2  XRCC1 Polymorphism Arg399Gln and MGMT 
polymorphisms Leu84Phe and Ile143Val and Gliomas among males and females 
 
    Some hereditary syndromes characterized by cancer predisposition are caused by mutations in DNA repair 
genes.  Mutation of repair genes significantly increases risk of cancer.  Therefore, common variants (SNPs) in 
the population may significantly contribute to the genetic risk of gliomas.  Studies have demonstrated that 
polymorphisms in DNA repair genes increase DNA adduct levels and chromosomal strand breaks making 
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transition to malignancy more likely.  Nucleotide alterations in the MGMT gene have been found in human 
tumor samples, including glioblastomas.  Furthermore, MGMT is located at chromosome 10q23, a region 
common deleted in gliomas.  Thus, induction of MGMT may be a critical repair function in gliomagenesis and 
individuals with MGMT polymorphisms may be more predisposed to gliomas.   Repair genes ERCC1 and 
ERCC2 have been associated with glioma subtypes which may be due not because of biologic causality, but 
because of statistical correlation with the true causal variant (e.g. linkage disequilibrium).  One such candidate 
gene is XRCC1, a critical repair gene responsible in repairing damage caused by smoking, a putative risk factor 
of gliomas.  By estimating the extent of linkage disequilibrium (LD) among these genes, the proximity of the 
true causal variant may be predicted depending on the variance of LD.  We predicted the variant genotypes in 
XRCC1 and MGMT will decrease the risk of adult onset gliomas, making these carriers more sensitive to 
environmental exposures. (Figure 2.2)  The specific aims of this study include the following:  
Aim 1:  To determine the frequencies of DNA repair gene XRCC1 polymorphism Arg399Gln and 
DNA repair protein MGMT polymorphisms Leu84Phe and Ile143Val among cases and controls 
participating in the population based San Francisco Adult Glioma Study. 
Aim 2: To determine risk of adult onset gliomas associated with XRCC1 polymorphism (Arg399Gln) 
and MGMT polymorphisms (Leuk84Phe and Ile143Val)  
Aim 3: To determine whether the effect of tobacco smoking on the risk of gliomas is modified by 
XRCC1 polymorphism Arg399Gln and MGMT polymorphisms Leu84Phen and Ile143Val 
Aim 4: To determine whether there is a gene-gene interaction between XRCC1 polymorphism 
Arg399Gln and DNA repair gene polymorphisms ERCC1 (A to C polymorphism at 3 UTR) and 
ERCC2 (Arg156Arg and Lys751Gln) 
Aim 5:  To determine whether risk associated with aforementioned DNA repair polymorphisms differ 
by age at diagnosis, gender, race/ethnicity, and tumor subtype 
B. Parent Study: San Francisco Adult Glioma Study 
 
1.   Subject selection 
 
    The San Francisco Adult Glioma Study is an on-going population based case control study whose primary 
research question is to evaluate genetic risk factors in relation to gliomas among men and women residing in six 
of San Francisco Bay area counties (Alameda, Contra Costa, Marin, San Mateo, San Francisco, and Santa 
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Clara).  Incidence rates for all races male and female in this area mirror the national average (SEER 1997-
2001).  Cases diagnosed with histologically confirmed incident gliomas (International Classification of Diseases 
for Oncology, morphology codes 9380-9481) between August 1991 to April 1994 (Series 1) and May 1997 to 
August 1999 (Series 2) were identified within a median of 7 weeks using the Northern California Rapid Case 
Ascertainment program.  After receiving permission from the potential subjects physician, cases were sent a 
letter describing the study and later contacted via telephone to enroll participants and schedule an in-person 
interview.  If the case was too ill or already dead, proxies were contacted directly with similar protocol as cases.  
Of the 1129 eligible glioma cases identified through this program, 89% (n=1001) agreed to participate.  The 
remaining 122 cases were excluded either because they were too ill or could not speak English (n=22), could 
not be located (n=47), could not confirm tumor was a glioma in neuropathology review (n=17), or could not get 
doctors consent to contact eligible case. Subsequently, only 873 cases (series 1 = 476 cases, series 2 = 403 
cases) were used in the parent study.   
    Control eligibility included competence in English and residency in the same San Francisco Bay Area 
counties in which cases arose.  Controls were identified using random digit dialing and frequency matched to 
cases by age (in 5 year age groups), race (White, Black, Hispanic, Asian, or other), and gender.  Of the 15,894 
phone numbers contacted, 8% (n=1316) were eligible controls.  Similar to cases, eligible controls were sent an 
introductory letter and telephoned to schedule an in-person interview.  Sixty six percent (n=864) completed the 
in person interview and 14% (n=184) an abbreviated telephone interview.  The other eligibles were dropped 
because either they refused (n=184), did not speak English or were too ill (n=17), were not located (n=43), or 
otherwise could not be used (n=39). A total of 864 controls over two series met eligibility requirements and 
agreed to participate.   
2.  Exposure assessment 
 
    Trained interviewers used a comprehensive questionnaire to obtain information pertaining to a wide array of 
environmental and genetic exposures.  Showcards were used in the personal interviews to provide standardized 
definitions to multiple choice answers and assist the participant with a visual reminder of plausible answers.  
Blood or buccal samples were obtained from willing participants for genotyping.   
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C.  Manuscript 1: Reproductive factors and hormone use and gliomas 
 
1. Study population 
 
    Details of the San Francisco Adult Glioma Study from which cases and controls for our proposed study were 
extracted were described in the Parent Study section above.  Eligible cases for this study were defined as 
women aged 20 years and older with histologically confirmed incident glioma (International Classification of 
Diseases for Oncology, morphology codes 9380-9481) in six San Francisco Bay Area counties (Alameda, 
Contra Costa, Marin, Can Mateo, San Francisco, and Santa Clara) from August 1991 to April 1994 (series 1) 
and from May 1997 to August 1999 (series 2).  Eligible controls included women aged 20 years and older 
without a diagnosis of brain cancer within the same time periods.  Controls were frequency matched to cases by 
age (in 5 year age groups), race (White, Black, Hispanic, Asian, or other), and gender.  
2.  Exposure assessment 
 
    Exposure information was collected in an interview where female participants or their proxies were asked to 
recall their reproductive and menstrual histories and exogenous hormone use.  Questions asked included age at 
first menstrual period, age menstrual periods stopped completely, number of live births, number of pregnancies 
not surviving to term, age at each birth, oral contraceptive use (ever/never, never/former/current) and duration 
(years or months), and ever hormone replacement therapy use (ever/never, never/former/current) and duration 
(years or months). Menopausal status was determined by whether they were still menstruating (choices 
included: yes; yes, but pregnant or postpartum; yes, but infrequently, probably perimenopausal; yes, but taking 
menopausal estrogen now) or were no longer menstruating (choices included no, went through natural 
menopause; no, had a hysterectomy; no; other).  If they reported having a hysterectomy, further inquiry was 
made into type of surgery (womb removed, womb and both ovaries removed, womb and 1 ovary removed, one 
or both ovaries removed, type unknown).   
    Gliomas are typically more common in whites and persons of higher socioeconomic status.  Educational 
degree obtained, annual household income, and race are important markers of socioeconomic position.1,2,3 
Education degree was collected in the parent student as a 10 level variable (less than high school, high school, 
junior college or lvn, college, rn, masters, phd or jd, md or dds or dvm, dont know, other).  Annual household 
income was collected as a 9 level variable ($1-10,000, $20-29,000, $30-49,000, $50-69,000, $70-99,000, 
$100,000+, dont know).  Race/ethnicity was collected as other Asian, Black, Chinese, Filipino, other Hispanic, 
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Japanese, Mexican, other, White).  Although categorizing the data more finely can be advantageous to assessing 
whether confounding is introduced by merging into smaller categories,4 numbers did not support the high level 
categorization used.  Since preliminary analysis indicated a high correlation between race, education, and 
income, we included only race for a more parsimonious model.  
    Other covariates of interest such as body mass index, smoking, age at diagnosis, and glioma subtype were 
abstracted from the parent questionnaire or the neuropathology report.  Cigarette smoking was selected a prior 
for examination of interaction with reproductive and menstrual factors.  Ever smokers were defined as those 
subjects who reported smoking more than 100 cigarettes over their lifetime.  Other forms of tobacco (such as 
cigars and pipes) were not assessed in this analysis, nor was second-hand smoke exposure.  Height and weight 
data were collected only in series two subjects limiting power to analyze the effect of BMI.  More importantly, 
height and weight measurements were collected at the time of the interview, which for cases was often after 
they had already gone through chemotherapy.  Since gliomas are often accompanied by unexplained weight loss 
in addition to the weight loss caused by chemotherapy, we cannot rely on these measurements as reflective of 
what body mass was prior to cancer incidence and therefore did not include BMI in this study.   
3. Study power 
 
    Power analyses for main effects and potential reproductive-smoking interactions were conducted using the 
NCI Power program (version 3.0.0).  All tests performed were two-sided with an α=0.05.  Preliminary power 
calculations indicate that this study had limited power to detect reasonable odds ratios.  This analysis had 
adequate power (≥80%) to detect a minimum OR of 1.7 for most reproductive factors.  However, there was 
substantially less power for hormone duration variables and gravidity. (Table 2.1)  Stratified analysis by 
histologic type was not well powered.  The most common glioma subtype, GBM, required a minimum OR = 2.0 
to obtain adequate power.  Likewise, the interaction between smoking and reproductive factors required 
relatively large odds ratios (at least OR=3.6) for adequate power. (Table 2.2)  Any analysis by subtype or 
analysis of reproductive factor-smoking interaction should be considered preliminary and hypothesis generating 
rather than etiologically meaningful.   
4.  Methodologic considerations 
 
    In this study, as is typical of case control studies investigating fatal cancers, high proxy participation was 
unavoidable.  Exclusion of proxies was not preferable as it would limit sample size and findings may still suffer 
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from both a misclassification bias and case selection bias.  Stratifying results by proxy status afforded us an 
opportunity to describe the potential consequences of misclassification that may occur differentially with the 
outcome, since proxy respondents were essentially restricted to cases (cases=42% proxy vs. controls < 1% 
proxy).  Preliminary analyses using crude case-case odds ratios illustrated that proxy cases were significantly 
less likely to report no hormone replacement and no children as compared to self-report cases.  The latter is 
likely due to a real difference in parity between cases that were self-reported versus proxy reported given the 
high likelihood that proxies are able to accurately report whether or not the case had children.  Proxy cases were 
significantly more likely to report postmenopausal status, characterize menopause as occurring naturally, and 
report no birth control pill use as compared to self-reporters.  Proxies tended to report an earlier age at menarche 
than self-reports, but there was little difference in recall of menopausal age. (Tables 2.3 and 2.4)  Greater than 
10% of cases were missing data and subsequently excluded from the analysis of age at menarche, age at 
menopause, and postmenopausal hormone duration due to missing data as compared to <1% of controls 
indicating missing data was differential with regard to case-control status.   
    There is no standard formula to calculate a quantitative measure of cumulative hormone exposure.  Previous 
authors have equated total exposure with reproductive period (age at menopause minus age at menarche).5,6,7  
Kleijn and colleagues expanded on this formula by including events known to change the hormonal 
environment.  For each child, 9 months were subtracted for each miscarriage/stillborn, 3 months subtracted for 
each breastfed child, and 4 months subtracted for total duration of OC use.8  Others recommended subtracting 
the sum of the duration of pregnancies and breastfeedings from the reproductive period,9 while another reported 
findings simply using the years of menstruation added to duration of postmenopausal HRT use.10  When 
assessing mortality risk, these formulas were not found to be superior to using only menopausal age to obtain an 
estimate of lifetime estrogen exposure.11 We determined what the associations might be using different 
definitions of lifetime hormonal exposure.  Formulas including information on breastfeeding and abortion were 
excluded from the analysis since our study did not collect these variables.    
D.  Manuscript 2:  DNA repair polymorphisms XRCC1 Arg399Gln, MGMT Leu84Phe, and MGMT 
Ile143Val and gliomas 
 
1.  Study population 
 
    Details of the San Francisco Adult Glioma Study from which cases and controls were extracted for our 
proposed study were described in the Parent Study section above.  Eligible cases were defined as men and 
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women aged 20 years and older with histologically confirmed incident glioma (International Classification of 
Diseases for Oncology, morphology codes 9380-9481) in six San Francisco Bay Area counties (Alameda, 
Contra Costa, Marin, Can Mateo, San Francisco, and Santa Clara) from August 1991 to April 1994 (series 1) 
and from May 1997 to August 1999 (series 2).  Cases were identified within a median of 7 weeks of diagnosis 
using the Northern California Ascertainment Program. 12,13  Eligible controls included men and women without a 
diagnosis of brain cancer within the same time periods.  Controls were frequency matched to cases by age (in 5 
year age groups), race (White, Black, Hispanic, Asian, or other), and gender.  
2.  Exposure assessment 
 
    We extracted data from the parent study pertaining to sociodemographic characteristics and smoking use.  
Smoking history, a potential effect modifier in this proposed study of XRCC1 and MGMT polymorphisms, was 
obtained by asking whether or not the subject had ever smoked cigarettes.  Persons were categorized as ever 
smoked if they had smoked 100 tobacco cigarettes over the course of their life.  Further questions were asked 
for ever smokers including current smoking status (current or former), years smoked cigarettes, and years 
smoking less than one-half pack a day, one-half to one pack, one pack to two packs, more than two packs a day, 
or unknown frequency.    
3. DNA extraction and genotyping procedure 
 
    Blood specimens were collected from willing cases and controls partway through the first series when 
funding was received.  All participants in series 2 were asked to donate either blood and/or buccal specimens.  
In total, specimens were obtained from 461 case participants (52% of participating cases) and 558 control 
participants (65% of participating controls).  Using the QIAamp Blood Kit (QIAGEN, Hilden, Germany), 
genomic DNA was extracted from whole blood. XRCC1 genotype was assayed using a polymerase chain 
reaction (PCR) followed by restriction fragment length polymorphism (RFLP). The XRCC1-Arg399Gln 
polymorphism was determined using a 50 l reaction volume containing 0.3 ng of DNA, 0.2 mM of each primer 
(sense:5CCAAGTACAGCCAGGTCCTA-3 and antisense: 5-AGTCTGACTCCCCTCCGGAT-3), 1.25 
units of taq DNA polymerase (Perkin-Elmer, Branchburg, NJ), 1.25 mM of dNTP, 10mM Tris-HCl, pH 8.3 (at 
25 C), 50 mM KCl, 1.5 mM MgCl2, and 0.001% (W/V) gelatin.  PCR cycle conditions were: holding at 94 C 
for 5 minutes; then 35 cycles of denaturation at 94 C, annealing at 60C, and extension at 72 C for 1 minute. 
After amplification, PCR products were digested with MspI (New England Biolabs), as described by the 
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supplier. Each digested sample was electrophoresed in agarose gel in TBE bufffer. The gel then was stained 
with ethidium bromide, visualized on a transilluminator under UV light, and photographed.   For quality control 
purposes, laboratory personnel were blinded to case-control status and both negative and positive controls 
(including every 10th sample as a blinded duplicate) were included. 
    MGMT genotypes was assayed using an allelic discrimination 5-nuclease assay (Taqman) on the ABI 
PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) in 96 well format.  Taqman 
primers and probes were designed using the Primer Oligo Design Software v2.0 (Applied Biosystems).  Primers 
for the amplification of MGMT Leu84Phe were f- CCCGAGGCTATCGAAGAGTTC and r-
CCGACCTTGCTGGAAAACG.  Probes used for detection of MGMT Ile84Val SNP were vic-
ATGGTGAAGAGCCGG-NFQ and fam-ATGGTGAAAAGCCGG-NFQ.  Primers for the amplification of 
MGMT Ile143Val were f-TGCCCCCCTGTCTTCCA and r-GCTGCTGCAGACCACTCT.  Probes used for 
vic-CCCATCCTCATCCCGT-NFQ and fam-CCCATCCTCGTCCCGT-NFQ. 
    Methods used for genotyping ERCC1 and ERCC2 have been previously described.14,15,16   
4.  Study power 
    Power analysis for main effects and potential gene-smoking and gene-gene interactions was conducted using 
the NCI Power program (version 3.0.0).  All tests performed were two-sided with an α=0.05.  Our analyses had 
85% power to detect a minimum OR of 1.5 for variant repair gene XRCC1 at codon 399.  MGMT 
polymorphisms needed slightly stronger risk estimates (OR=1.7) to obtain similar power. (Table 2.6)  Joint risk 
between ever/never smoking and relevant repair genes from both NER and BER pathways needed to be large 
(preferably joint OR=3.0 or greater) to obtain adequate power. (Table 2.7)  In the gene-gene interactions, power 
to detect a minimum joint OR of 4.32 was strongest in the XRCC1 at codon 399 and ERCC1 variant (71%).  
XRCC1 and ERCC2 polymorphisms required at least an OR of 5.04 to demonstrate satisfactory power. (Table 
2.8)  
5. Methodologic considerations 
 
    Gliomas are relatively rare compared to more common cancers such as skin.  This study was large compared 
to other glioma studies but still hampered by the small number of cases available.  Due to the heterogeneous 
nature of gliomas, stratification by histologic subtypes is necessary to correctly identify potential causes yet 
detrimental to the power of the analysis as it will limit number of available cases, particularly in interaction 
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analyses.  We originally anticipated analyzing all five variants simultaneously in the gene-gene interaction 
using penalized quasi-likelihood regression modeling (PQL) to obtain more stable estimates than could be 
achieved using conventional likelihood models of small study sizes.  However, analysis of the 2-way gene-gene 
interactions hovered around the null, indicating that the PQL procedure would not meaningfully add to the 
interpretation of results.   
    A positive association between DNA repair polymorphisms and glioma may reflect either an alteration in the 
repair proteins themselves, linkage disequilibrium, population stratification, or chance.  Population stratification 
was not of grave concern given our study population was predominantly white. Furthermore, we did not observe 
evidence of association between XRCC1, ERCC1, and ERCC2 to indicate linkage disequilibrium.  Chance may 
still be a viable explanation given the small sample sizes.       
    In the parent case control study, participants were asked to recall their lifetime smoking history.  Potentially 
problematic issues include the differential recall and categorization of reported measures.  Remembering and 
reporting smoking histories differently from cases and controls may result in bias either away or toward the 
null.  We may expect both differential and non-differential misclassification will bias a multiplicative 
interaction affect toward the null if smoking is independent of the relevant genotype (assuming both are binary 
variables).17  The direction of bias on an additive scale may move in either direction.        
    It is noted as with other studies of highly fatal cancers that collection of DNA specimens was limited to the 
living cases.  Thus, some genotypes may be associated with survival, possibly biasing results.  Missing data 
may affect case-subtype analysis given the majority of non-genotyped participants were cases and more likely 
to be the more fatal GBM than non-GBM subtypes.  A recent study using this dataset did not find a relationship 
of survival by XRCC1 and MGMT genotypes.  To account for the non-genotyped GBM cases, we performed 
sensitivity analyses under hypothetical scenarios that assume missing cases were more likely to have the variant 
genotype or the non-variant genotype.  Using plausible ranges of 35-50% for XRCC1 and 70-85% for MGMT 
genotypes, we observed no notable changes in risk estimates (<5% change). 
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E. Figures and tables 
Figure and tables for Manuscript 1 
 
 
Figure 2.1:  Hypothesized link between reproductive factors and gliomas 
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Table 2.1: Power calculations for main effects of reproductive variables and gliomasω 
 
Reproductive 
variable 
P(R) #cases/controls Minimum 
detectable effect 
Power (%) 
Parity 
(referent = yes) 
0.21 
0.21 
0.21 
381/394 
381/394 
381/394 
1.3 
1.5 
1.7 
30 
59 
81 
Gravidity 
(referent = no) 
0.73 
0.73 
0.73 
187/207 
187/207 
187/207 
1.3 
1.5 
1.7 
20 
39 
58 
OC use 
(referent = yes) 
0.47 
0.47 
0.47 
364/393 
364/393 
364/393 
1.3 
1.5 
1.7 
42 
78 
95 
HRT use 
(referent = yes) 
0.59 
0.59 
0.59 
360/392 
360/392 
360/392 
1.3 
1.5 
1.7 
41 
76 
94 
OC use - duration 
(>12 months 
referent) 
0.18 
0.18 
0.18 
167/227 
167/227 
167/227 
1.3 
1.5 
1.7 
14 
27 
41 
HRT use - duration 
(>12 months 
referent) 
0.17 
0.17 
0.17 
112/181 
112/181 
112/181 
1.3 
1.5 
1.7 
11 
19 
28 
Age at menarche 
(>13 years referent) 
0.45 
0.45 
0.45 
315/390 
315/390 
315/390 
1.3 
1.5 
1.7 
37 
71 
91 
Age at menopause 
(≥ 46 years referent) 
0.41 
0.41 
0.41 
214/239 
214/239 
214/239 
1.3 
1.5 
1.7 
26 
53 
76 
Age at first birth 
(≥24 years referent) 
0.52 
0.52 
0.52 
297/310 
297/310 
297/310 
1.3 
1.5 
1.7 
36 
69 
90 
Reproductive period 
(≥ 36 years referent) 
0.70 
0.70 
0.70 
315/390 
315/390 
315/390 
1.3 
1.5 
1.7 
32 
63 
85 
P(R): proportion of study population with exposed level of reproductive variable 
ω: All tests performed were two-sided with an α=0.05 
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Table 2.2: Power calculations for interactions between reproductive factors and ever cigarette smokingω in 
relation to gliomas 
 
Reproductive 
Factor 
P (S) P(R) OR (R) OR (S) θ (RS) # 
cases/controls 
Power 
(%) 
Parity 
(referent = yes) 
0.49 
0.49 
0.49 
0.21 
0.21 
0.21 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
380/394 
380/394 
380/394 
47 
70 
84 
Gravidity 
(referent = no) 
 
0.49 
0.49 
0.49 
0.27 
0.27 
0.27 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
187/207 
187/207 
187/207 
30 
47 
61 
OC use 
(referent = yes) 
 
0.49 
0.49 
0.49 
0.47 
0.47 
0.47 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
364/393 
364/393 
364/393 
63 
85 
95 
HRT use 
(referent = yes) 
0.49 
0.49 
0.49 
0.59 
0.59 
0.59 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
360/392 
360/392 
360/392 
60 
82 
93 
OC use  duration 
(>24 month 
referent) 
0.49 
0.49 
0.49 
0.28 
0.28 
0.28 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
167/227 
167/227 
167/227 
28 
44 
58 
HRT use  
duration 
(>24 month 
referent) 
0.49 
0.49 
0.49 
0.17 
0.17 
0.17 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
112/181 
112/181 
112/181 
21 
32 
42 
Age at menarche 
(>13 referent) 
0.49 
0.49 
0.49 
0.45 
0.45 
0.45 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
315/390 
315/390 
315/390 
57 
80 
91 
Age at menopause 
(≥46 referent) 
0.49 
0.49 
0.49 
0.41 
0.41 
0.41 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
214/239 
214/239 
214/239 
41 
62 
77 
Age at first birth 
(≥ 24 referent) 
0.49 
0.49 
0.49 
0.52 
0.52 
0.52 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
297/310 
297/310 
297/310 
54 
77 
90 
Reproductive 
period 
(≥ 36 years 
referent) 
0.49 
0.49 
0.49 
0.70 
0.70 
0.70 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
315/390 
315/390 
315/390 
47 
69 
83 
P(S): proportion of study population ever smoking  
P(R): proportion of study population with exposed reproductive variable 
OR(R): estimated risk due to exposed level of reproductive variable alone 
OR(S): estimated risk due to ever smoking alone 
ω: All tests performed were two-sided with an α=0.05 
θ (RS): proportionality factor at the highest categories for each exposure relative to the lowest categories 
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Table 2.3: Frequencies and percentages of reproductive factors and hormone use in relation to gliomas by proxy 
status: case-case odds ratios   
 
Reproductive  Variable Case (%) Control (%) OR (95% CI) 
Parity    
     Proportion proxy 159 (42)  2 (    1)  
     Yes 299 (78) 310 (  77) 1.00 
     No  self report 64 (78) 84 (100)  
     No  proxy 18 (22) 0 (    0) 0.25 (0.14, 0.44) 
Gravidity    
     Proportion proxy 91 (49) 2 (  <1)  
     No 145 (78) 143 (  69) 1.00 
     Yes  self report 20 (48) 64 (100)  
     Yes  proxy 22 (52) 0 (    0) 1.21 (0.61, 2.40) 
Birth control pill use    
     Proportion proxy 142 (39) 2 (  1)  
     Yes 176 (48) 227 (58) 1.00 
     No  self report 84 (45) 165 (99)  
     No - proxy 104 (55) 1 (  1) 4.50 (2.83, 7.10) 
Hormone replacement use    
     Proportion proxy 141 (39) 2 (  1)  
     Yes 127 (35) 183 (47) 1.00 
     No  self report 151 (65) 208 (99)  
     No  proxy 82 (35) 1 (<1) 0.63 (0.40, 0.98) 
Birth control pill duration    
     Proportion proxy 31 (16) 1 (<1)  
     ≥ 2 year 126 (75) 159 (70) 1.00 
     < 2 year  self report 37 (90) 67 (99)  
     < 2 year  proxy 4 (10) 1 (<1) 0.40 (0.13, 1.22) 
Hormonal replacement duration    
     Proportion proxy 48 (43) 1 (  1)  
     ≥ 2 year 90 (80) 122 (67) 1.00 
     < 2 year  self report 14 (64) 58 (98)  
     < 2 year  proxy 8 (36) 1 (  2) 0.71 (0.54, 3.69) 
Age at first birth    
     Proportion proxy 140 (47)     2 (    1)  
     ≤ 24 years old 157 (53) 156 (  50) 1.00 
     > 24 years old  self report 82 (59) 154 (100)  
     > 24 years old - proxy 58 (41) 0 (    0) 0.65 (0.41, 1.03) 
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Table 2.4:  Frequencies and percentages of menstrual factors in relation to gliomas by proxy status: case-case 
odds ratios   
 
Menstrual Variables Case (%) Control (%) OR (95% CI) 
Age at menarche    
     Proportion proxy 93 (30) 1 (<1)  
     < 13 years old 149 (47) 172 (44) 1.00 
     ≥ 13 years old  self report 119 (72) 217 (99)  
     ≥ 13 years old  proxy 47 (28) 1 (<1) 0.88 (0.54, 1.43) 
Age at menopause    
     Proportion proxy 111 (52) 1 (<1)  
     > 46 years old 124 (58) 142 (59) 1.00 
     ≤ 46 years old  self report 43 (48) 96 (99)  
     ≤ 46 years old - proxy 47 (52) 1 (<1) 1.02 (0.59, 1.76) 
Menopausal status    
     Proportion proxy 151 (40)    2 (  1)  
     Premenopausal 125 (34) 153 (39) 1.00 
     Postmenopausal  self report 111 (45) 239 (99)  
     Postmenopausal - proxy 137 (55) 2 (<1) 9.80 (5.32, 17.95) 
Menopausal type    
     Proportion proxy 136 (55) 2 (    1)  
     Natural 143 (58) 157 (  65) 1.00 
     Surgical  self report 42 (46) 80 (100)  
     Surgical - proxy 50 (54) 0 (    0) 0.89 (0.53, 1.51) 
     Other  self report 8 (67) 3 (100)  
     Other - proxy 4 (33) 0 (    0) 0.37 (0.11, 1.28) 
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Figure and tables for Manuscript 2 
 
 
Figure 2.2:  Hypothesized link between smoking and DNA repair genes and gliomas 
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Table 2.5: Power calculations for the main effects of XRCC1 polymorphism at codon 399 and MGMT 
polymorphisms at codons 84 and 143 in association with gliomasω 
 
Among all participants Whites only  
 
Gene 
#cases/controls Minimum 
detectable 
effect 
Power 
(%) 
#cases/controls Minimum 
detectable 
effect 
Power 
(%) 
XRCC1 codon 
399 
 
 
 
MGMT codon 143 
 
 
 
MGMT codon 84 
441/487 
 
 
 
459/490 
 
 
 
477/502 
 
1.3 
1.5 
1.7 
 
1.3 
1.5 
1.7 
 
1.3 
1.5 
1.7 
49 
85 
97 
 
33 
65 
86 
 
39 
73 
92 
366/427 
 
 
 
370/419 
 
 
 
385/430 
1.3 
1.5 
1.7 
 
1.3 
1.5 
1.7 
 
1.3 
1.5 
1.7 
42 
77 
94 
 
28 
56 
79 
 
32 
64 
85 
ω: All tests performed were two-sided with an α=0.05 
Note: assuming dominant model and using homozygous wild type as exposed group 
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Table 2.6: Power calculations for interaction between DNA repair polymorphisms and ever cigarette smoking in 
association with gliomas ω 
 
Gene  P(E) P(G) OR(G) OR(E) θ(GE) # 
cases/controls 
Power 
(%) 
XRCC1 
at codon 
399 
All 
races 
0.53 
0.53 
0.53 
0.44 
0.44 
0.44 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
439/487 
439/487 
439/487 
70 
90 
97 
 Whites 0.53 
0.53 
0.53 
0.43 
0.43 
0.43 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
365/427 
365/427 
365/427 
62 
84 
94 
MGMT 
at codon 
84 
All 
races 
0.54 
0.54 
0.54 
0.22 
0.22 
0.22 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
474/502 
474/502 
474/502 
57 
79 
91 
 Whites 0.54 
0.54 
0.54 
0.22 
0.22 
0.22 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
385/430 
385/430 
385/430 
48 
71 
84 
MGMT 
at codon 
143 
All 
races 
0.54 
0.54 
0.54 
0.18 
0.18 
0.18 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
457/490 
457/490 
457/490 
49 
71 
85 
 Whites 0.55 
0.55 
0.55 
0.18 
0.18 
0.18 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
370/419 
370/419 
370/419 
42 
63 
77 
ω: All tests performed were two-sided with an α=0.05 
P(E): Proportion of study population who ever smoked 
P(G): Proportion of study population with ww genotype (except in MGMT where exposed is wv/vv genotype) 
OR(G): estimated risk due to ww genotype (or wv/vv genotype as in the case of MGMT) 
OR(E): estimated risk due to ever smoking  
Θ(GE): proportionality factor at the highest categories for each exposure relative to the lowest categories 
Note: assuming dominant model and using (homozygous wild type as exposed group) 
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Table 2.7: Power calculations for two-way interactions between DNA repair polymorphisms XRCC1, ERCC1, 
and ERCC2 in association with gliomas ω 
 
Gene PG1 PG2 ORG1 ORG2 θG1,G2 # cases/controls Power 
(%) 
All races        
XRCC1 and ERCC2 
codon 156 
0.45 
0.45 
0.45 
0.31 
0.31 
0.31 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
394/458 
394/458 
394/458 
57 
80 
91 
XRCC1 and ERCC2 
codon 751 
 
0.44 
0.44 
0.44 
0.42 
0.42 
0.42 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
426/477 
426/477 
426/477 
67 
88 
96 
XRCC1 and ERCC1 
 
 
0.44 
0.44 
0.44 
0.52 
0.52 
0.52 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
440/487 
440/487 
440/487 
70 
90 
97 
Whites only        
XRCC1 and ERCC2 
codon 156 
0.43 
0.43 
0.43 
0.30 
0.30 
0.30 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
331/401 
331/401 
331/401 
48 
71 
84 
XRCC1 and ERCC2 
codon 751 
 
0.42 
0.42 
0.42 
0.38 
0.38 
0.38 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
352/417 
352/417 
352/417 
56 
78 
90 
XRCC1 and ERCC1 
 
 
0.43 
0.43 
0.43 
0.53 
0.53 
0.53 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
2.0 
2.5 
3.0 
366/427 
366/427 
366/427 
62 
84 
94 
ω: All tests performed were two-sided with an α=0.05 
P G1: Proportion of study population with XRCC1 ww genotype 
P G2 : Proportion of study population with respective ERCC ww genotype 
OR G1:  estimated risk due to XRCC1 ww genotype 
OR G2: estimated risk due to respective ERCC ww genotype  
θG1,G2: proportionality factor at the highest categories for each exposure relative to the lowest categories 
Note: assuming dominant model,  using homozygous wild type as exposed group 
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CHAPTER III:  REPRODUCTIVE FACTORS AND HORMONE USE AND RISK OF GLIOMAS 
 
A.  Abstract 
 
    The most consistent risk factor for gliomas is the excess of male cases.  Other evidence suggesting a 
hormonal influence includes hormone receptors in glial tumors and a change in incidence rates around age at 
menarche and menopause.  Results from previous epidemiologic studies of reproductive factors and gliomas 
have been largely inconclusive due, in part, to imperfect measures of reproductive and menstrual history and 
few cases.  Using a large population based case control study, we investigated whether reproductive factors and 
hormone use were associated with gliomas as a group or if associations were present specific to tumor subtype.  
Measures of cumulative hormone exposure were evaluated as well.  Statistical analyses were performed on 387 
female cases diagnosed between August 1991 to April 1994 and May 1997 to August 1999.  Female controls 
(n=392) were identified using random digit dialing and frequency matched by age and race.  Overall, 
reproductive and menstrual factors were not associated with the risk of gliomas regardless of tumor subtype.  
Inverse associations were observed for ever exogenous hormone use (oral contraceptive use: OR = 0.73, 95% 
confidence interval, 0.49-1.10; postmenopausal hormone use: OR = 0.53, 95% CI: 0.33-0.86).  Effect estimates 
decreased with increasing duration of oral contraceptive use among ever users.  There was some suggestion of a 
weak interaction between oral contraceptive use and postmenopausal hormone use.  Cumulative hormone 
exposure defined multiple ways demonstrated no clear pattern of association.  The results of this study suggest 
that exogenous hormone use may play a role in gliomagenesis among women, but larger studies and a more 
detailed history of exogenous hormone use are needed to confirm findings.  
B.  Introduction 
 
    Gliomas are the most common and potentially most deadly of all primary brain tumors.1,2  Despite 
investigations into environmental, occupational, infectious, and lifestyle exposures, the etiology of gliomas 
remains largely unknown.  The most consistent finding among epidemiologic studies is the higher incidence 
rates in males as compared to females.3 The causes for the disproportionate incidence rates between genders 
continue to elude identification. Previous animal and epidemiology studies suggest that sex hormones may play 
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a role.  Empirical support for a hormonal effect includes the presence of hormone receptors in normal glial cells 
4,5 and glial tumors 6,7,8,9,10, higher rates of glioma after menopause than expected in premenopausal women, and 
notable points of change in rates around the time of menarche and menopause.11 Plausible mechanisms by which 
sex hormones may play a role in gliomagenesis have been postulated12,13,14,15, but epidemiologic studies using 
reproductive and menstrual history as surrogates of hormone exposure have been inconsistent.16,17,18,19,20,21,22 
Reasons for this are unclear but could be due to small sample sizes, different histology groupings among glioma 
classification systems, lumping heterogeneous histologic subtypes, or using surrogate hormone variables 
indicative of only one point in time. We used data from the large population-based San Francisco Adult Glioma 
Study to estimate the effects of reproductive factors and hormone use on glioma risk among women. Ages at 
menarche and menopause and years of exogenous hormone use were used as indicators of cumulative female 
hormone exposure to more completely characterize dose-response relationships.   
C. Materials and Methods 
 
1.  Study participants 
 
    The present study used data from the San Francisco Adult Glioma study described previously.  Cases 
diagnosed with histologically confirmed incident gliomas (International Classification of Diseases for 
Oncology, morphology codes 9380-9481) between August 1991 to April 1994 (Series 1) and May 1997 to 
August 1999 (Series 2) were identified using the Northern California Rapid Case Ascertainment program.  
Controls were identified using random digit dialing and randomly selected for competence in English and 
residency in the same counties in which cases arose.  Controls were frequency matched to cases by age (in 5 
year age groups), race (White, Black, Hispanic, Asian, or other), and gender.  Of the 15,894 phone numbers 
contacted, 8% (n=1316) were eligible controls.  Sixty six percent (n=864) completed the in person interview 
and 14% (n=184) an abbreviated telephone interview.  The other eligibles were dropped because either they 
refused (n=184), did not speak English or were too ill (n=17), were not located (n=43), or otherwise could not 
be used (n=39). A total of 873 glioma cases and 864 controls over two series met eligibility requirements and 
agreed to participate.  Eligible cases and controls for this study were restricted to females 20 years and older, 
leaving 381 cases and 394 controls available for analysis.     
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2. Exposure Assessment 
 
    Exposure information was collected from the histories of reproductive, menstrual, and exogenous hormone 
use in female cases and controls.  On average, self-reporting cases were interviewed within 4 months and 
proxies within 8 months from diagnosis in the parent study.  Showcards were used in the personal interviews to 
provide standardized definitions to multiple choice answers and assist the participant with a visual reminder of 
plausible answers.  Questions asked included age at first menstrual period, age menstrual periods stopped 
completely, number of live births, number of pregnancies not surviving to term (question asked only in series 
1), age at each birth, oral contraceptive use (ever/never, never/former/current) and duration (years or months), 
and ever hormone replacement therapy use (ever/never, never/former/current) and duration (years or months). 
Menopausal status was determined by whether they were still menstruating (choices included: yes; yes, but 
pregnant or postpartum; yes, but infrequently, probably perimenopausal; yes, but taking menopausal estrogen 
now) or were no longer menstruating (choices included no, went through natural menopause; no, had a 
hysterectomy; no; other).  If they reported having a hysterectomy, further inquiry was made into type of surgery 
(womb removed, womb and both ovaries removed, womb and 1 ovary removed, one or both ovaries removed, 
type unknown).  Due to small numbers, types of surgery was combined into a single variable, surgical 
menopause. Women reporting partial hysterectomies were categorized as premenopausal; women reporting 
natural menopause or bilateral oopherectomy were categorized as postmenopausal.  Duration of exogenous 
hormone use was assessed by requiring subjects to recall the total number of years and/or months of oral 
contraceptive or female hormone use.  Cumulative hormone exposure was evaluated as menstruation years (age 
at menopause minus age at menarche) and menstruation years plus years of postmenopausal hormone use.  
Other covariates of interest included ever cigarette smoking (smoked more than 100 cigarettes throughout 
lifetime), race, education degree, age at diagnosis, and histologic glioma subtype.  
3.  Data Analysis 
 
    Category boundaries for continuous variables were determined by univariate quartile distributions among 
controls provided such cutpoints were biologically significant and contained more than 5 persons within each 
cell.  Differences in baseline characteristics between cases and controls were compared using χ2 tests and 
students t tests.  Odds ratios and 95% confidence intervals using unconditional logistic regression models were 
calculated for each reproductive, menstrual, and exogenous hormone factor independently among female cases 
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and controls.  Since odds ratios between series were similar (less than 2% difference) and adding series to the 
model containing other predictors of glioma did not change the odds ratio by more than 10 percent, series was 
not included in the final model.  In the same manner, we evaluated race (white, non-white), education degree, 
cigarette smoking, and menopausal status for confounding. Confounders were defined as covariates that 
changed the estimated exposure OR by greater than 10% after removal from model.  Final models were adjusted 
only for frequency matched factors age (continuous) and race (nonwhite, white).  Age at diagnosis, menopausal 
status and smoking were selected a priori as potential effect modifiers for selected reproductive factors and 
initially evaluated using the Breslow Day statistic (α = 0.20) to determine heterogeneity of the odds ratios 
between strata.   
    The combined effect of oral contraceptives and postmenopausal hormones was analyzed as a joint effect in 
multivariate modeling.  Comparisons were restricted to postmenopausal women who ever used both oral 
contraceptives and postmenopausal hormones relative to never users (e.g. users of oral contraceptives but not 
postmenopausal hormones and vice versa were not included).  We further evaluated whether there was 
interaction between duration of oral contraceptive use and ever postmenopausal hormone use, duration of 
postmenopausal hormone use and ever oral contraceptive use, and durations of oral contraceptive use and 
postmenopausal hormone use as continuous measures.  Effect measure modification was assessed on the 
multiplicative scale using the likelihood ratio test for adding the interaction term to the model without 
interaction terms.  Interaction on the additive scale was determined by comparing the observed odds ratio in the 
doubly exposed (oral contraceptive and postmenopausal hormone use) to the expected OR assuming additive 
risks.  
    To address concerns of recall bias, we further stratified analyses by proxy status.  Epidemiologic literature 
suggests proxy reporting of reproductive histories and hormonal use may be biased depending on the variable of 
interest and relationship of proxy to case.22,23  However, excluding proxies may result in a selection bias.24  Case-
case odds ratios between self-report cases and proxy cases were evaluated to evaluate the impact of proxy 
status.  
    Continuous variables for main effects were modeled to test for trend.  Beta coefficients and the p value of the 
Wald test were used to determine if slope differed from zero. Analyses of histologic type (GBM, non-GBM) 
specific associations compared each case subtype to the entire control group.   
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D.  Results 
 
    Analyses were based on 381 female cases and 394 female controls whose baseline characteristics largely 
mirrored male participants in the parent study except that females were slightly older and less educated. (Table 
3.1)  Cases were similar to controls except that cases were less educated.  Forty two percent of cases and 0.5% 
of controls were proxies.  Of the 162 proxies in this study, most were daughters (33%) and husbands (27%).  
Self-reporting cases were significantly younger than controls (mean age = 49.6 and 55.8, respectively, p < 
0.01), but otherwise similar in race, education, and smoking use.  The majority of tumors among cases were 
glioblastomas (60%).  Missing information with regard to baseline characteristics were distributed similarly 
between cases and controls. 
    The majority of females gave birth to at least one child (78%) and 40% of parous women had three or more 
children. (Table 3.2)  The mean age of menarche was 13 years and age at menopause was 46 years regardless of 
case or proxy status.  When considering only natural menopause, mean menopausal age increased to 50 years 
for cases and controls.  The majority of female participants were postmenopausal (63% of 767).  Of these, thirty 
eight percent reported a surgical procedure (eg. hysterectomy, oopherectomy) that initiated early menopause 
(<45 years old).  Approximately 52% reported ever oral contraceptive use and 57% reported ever 
postmenopausal hormone use.  Nearly a third of postmenopausal cases and controls who used oral 
contraceptives in the past went on to use postmenopausal hormones.  Sixty percent of cases and 40% of controls 
ever used both oral contraceptives and postmenopausal hormones. 
    Results of multivariate analyses are presented in tables for all women and restricted to self-report 
respondents.  We report risk estimates among self-report females only since risk estimates were not 
meaningfully altered by proxy status and self-report is assumed to be more accurate.   
    1. Reproductive factors 
    After adjusting for age and race, gliomas were not positively associated with parity (ORindex = 0.87, 95% CI: 
0.58-1.30), nor gravidity (ORindex = 0.70, 95% CI: 0.39-1.28, Table 3.2).  Odds ratios for increasing number of 
children (β = 0.08, p trend = 0.36) and increasing age at first birth (β = -0.01, p trend = 0.51) were near unity.  
Risk estimates did not meaningfully change by menopausal status (data not shown).     
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  2.  Menstrual factors 
    There was little evidence for an association between glioma risk and menarcheal age or menopausal age 
among self-reporting respondents. (Table 3.2)  Nearly identical odds ratios were observed for earlier and later 
ages at menarche relative to 12-13 years old (ORindex = 1.17, 95% CI: 0.75-1.82 and ORindex = 1.18, 95% CI: 
0.79-1.75, respectively).  This pattern remained when stratifying by menopausal status. (Table 3.3)  
Postmenopausal women experiencing a later age at menarche (≥ 14 years) and early onset of menopause (<50 
years old) were not at greater risk of gliomas than postmenopausal women with earlier age (<11 years) and later 
age of menopause (≥ 50 years), but estimates were imprecise. 
    Higher odds ratio estimates for gliomas were found among postmenopausal women relative to 
premenopausal women (ORindex = 1.57, 95% CI: 0.89-2.76, Table 3.2).  This association varied little by type of 
menopausal onset (e.g. natural, surgical).  We found a weakly elevated odds ratios with older age at menopause 
(≥50 years old: ORindex = 1.13, 95% CI: 0.60-2.11 relative to <45 years old, p trend = 0.43).  To compare our 
results with a previous study, we further examined menstruation years.  A significantly increased odds ratio was 
observed with greater number of menstruation years (25-34 years: ORindex = 1.63, 95% CI: 1.03-2.58 relative to 
<25 years), but an increasing trend was not apparent (β = 0.01, p trend = 0.23).  This risk estimate increased 
when restricted to women reporting surgical menopause (ORindex = 2.08, 95% CI: 1.17-3.68) and glioblastoma 
cases (ORindex = 2.23, 95% CI: 1.12-4.42, data not shown).    
    3. Exogenous hormone use 
    Risk estimates for exogenous hormone use consistently remained below 1.0.  A suggestive inverse 
association was observed for ever oral contraceptive use (ORindex = 0.73, 95% CI: 0.49-1.10, Table 3.4).  We 
observed decreasing odds ratios with longer duration of use among ever users (β = -0.01, p trend = 0.05).  
Associations between ever oral contraceptive use and gliomas were not modified by age at diagnosis (Breslow-
Day p value greater than 0.20) but odds ratios significantly decreased in women reporting surgically-induced 
menopause (ORindex = 0.39, 95% confidence interval, 0.16-0.98, data not shown).  
    Postmenopausal hormone use was inversely associated with glioma risk (ORindex = 0.53, 95% CI: 0.33-0.86).  
Current users had a significant decreased risk of gliomas (ORindex = 0.43, 95% CI: 0.24-0.74) relative to never 
users.  Although a greater proportion of female controls self-reported using postmenopausal hormones than 
cases, there was little difference in mean duration of use (125 months and 117 months, respectively).  Further 
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adjustment for age at menopause did not alter associations and evaluation of increasing duration did not reveal 
slope differed from zero (β < 0.01, p trend = 0.54, data not shown).    
    Postmenopausal women who reported using both oral contraceptives and postmenopausal hormones were at a 
reduced risk of gliomas (ORindex = 0.45, 95% CI: 0.21-0.99) relative to those who never used either hormone.  
The combined effects of oral contraceptives and postmenopausal hormones were very close to expectations for 
both additive (OR=0.50) and multiplicative (OR=0.54) models. (Table 3.5)  Longer duration of oral 
contraceptive use (≥10 years) conferred additional benefit with ever postmenopausal hormone use (joint OR = 
0.35 versus expected additive OR = 0.69) as did longer duration of postmenopausal hormone use with ever oral 
contraceptive use (joint OR = 0.41 versus expected additive OR = 0.65), but interpretation is limited due to 
small numbers in strata (data not shown).  
    Stratification by histologic tumor type did not appreciably alter risk estimates.  Similarly, exploratory 
analyses by smoking status did not uncover meaningful risk differences in the reproductive-glioma association . 
E. Discussion 
 
    Results from this population-based study indicate that there was no association between gliomas and 
gravidity, parity, number of children, and age at first birth.  Previous studies generally found a modest decrease 
in gliomas with higher parity and increased risk with greater age at first birth, which might be expected given 
women with more children are younger at age at first birth.  We did not find a decrease with higher parity which 
is not too surprising given the low parity of our population limited our statistical power to detect effects that 
might be apparent only with higher order births.  
    For the binary categorization of menopausal status, we used the distinction between women reporting partial 
hysterectomies and bilateral oopherectomy which yielded similar results to categorizing these women together 
as postmenopausal. There was no clear pattern of association with age at menopause even when excluding 
women with indeterminant menopausal status (ie, including only women reporting natural menopause or 
bilateral oopherectomy).  We did not find an inverse association with earlier age at menarche as was reported in 
a population based study of rural women. To compare findings with another study 25, we repeated the analyses 
using a similar categorization of age at menarche.  In contrast to our results that mainly hovered around the null, 
two studies reported increasing risk with older age at menarche.19,25   
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    The positive association between gliomas and menopausal status is difficult to interpret. A review of the 
literature indicates inconsistent findings are most likely due to the difficulty in accurately classifying women 
going through the perimenopausal transition.10,14,22  We would expect findings from women undergoing surgical 
menopause (particularly procedures which removed both ovaries) to be more revealing, but the small number of 
cases and controls reporting removal of both ovaries in our study prevented a precise analysis.  
    Our findings of inverse associations between gliomas and oral contraceptive use and postmenopausal 
hormone use agree with a multi-city hospital based case-control study,22 a population based case control study 
of rural women,12 and an international multi-center case-control study.10  Risk estimates for postmenopausal 
hormone use remained below 1.0 regardless of type of menopausal onset (surgical or natural), but risks were 
attenuated with early onset (<50 years of age) of menopause (data not shown).  The suggestive trend of 
decreasing odds ratios with increasing duration of oral contraceptive use is intriguing, but just may be a 
reflection of any oral contraceptive use.  To our knowledge, this is the first study to examine the combined 
effect of oral contraceptives and postmenopausal hormones.  Although there was some suggestion that past oral 
contraceptive use may influence a more beneficial postmenopausal hormone effect, we cannot rule out that 
women who use hormonal therapies are generally healthier. 26,27       
    We assessed cumulative exposure a number of ways to crudely account for variability of hormone 
fluctuations throughout reproductive life.  In our study, greater menstruation years demonstrated increasing risk 
with increasing years of potential hormonal exposure. This is in contrast to findings of decreasing risk estimates 
below the null with increasing number of menstruation months among rural women.12  Cumulative exposures 
defined to additionally include duration of postmenopausal hormones found the opposite, decreasing risk with 
increasing years of potential exposure.  The inconsistency between definitions of cumulative exposure used by 
previous authors 28,29,30 suggests more robust measures are needed to tease out potential differences in effect 
between exogenous and endogenous hormones.    
    Evidence from animal studies of the protective effect of estrogen on gliomagenesis and survival and the 
suggestive results from epidemiologic studies of reproductive factors led us to hypothesize that hormones would 
decrease risk of gliomas.  A growing literature supports the role of estrogen (and estrogen metabolistes, ME2) 
as a neuro-protectant, particularly in estrogen receptor independent pathways.31,32,33  In addition, estrogen has the 
ability to stimulate the most commonly activated signaling cascades in gliomas (AKT/PIP and 
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RAS/MAPK/Rb/CDK pathways) required for cell cycle control and induction of bcl-2 factors. Other hormones 
such as progesterone and placental hormones are known to restrict angiogenesis to vascular tumors;34 
glioblastomas are one of the most vascular of all solid tumors.  Our hypothesis predicts earlier age at menarche 
and later age at menopause, for example, should theoretically decrease glioma risk due to longer exposure to 
circulating estrogens, but parity should increase risk of gliomas due to interruptions in ovulatory cycles.  
Instead, we found little association with parity, age at menarche or menopause.  Reasons for this are unclear.  
Considering the daily production of placental estrogens increases to about 30 times normal toward the end of 
the pregnancy and the rate of progesterone secretion increases by as much as tenfold during the course of 
pregnancy,35,36,37 the short term protection afforded from these large hormonal spikes experienced in pregnancy 
may outweigh the long-term risk of hormonal fluctuations in the nervous system as opposed to, for example, 
estrogen effects in breast tissue.  Increasing risk with later age at menopause, as reported in some studies, still 
supports our hypothesis if exogenous estrogens administered at menopause provide a stronger protective effect 
than endogenous estrogens.38,39,40  Our study agrees with this supposition as reduced risk estimates for cumulative 
exposure were driven by synthetic hormone use as opposed to endogenous estrogens which tended to increase 
risk with greater menstruation years.   
    Of the relatively few studies examining reproductive factors and glioma risk, most were based on small 
numbers and limited to ever/never responses.  A strength of our study was the relatively large number of 
histologically confirmed glioma cases and more detailed information to detect subtle differences in the effect of 
potential cumulative hormonal exposure.  However, we cannot rule out the possibility that findings were due to 
other explanations, such as uncontrolled confounders including social correlates of the reproductive experience.  
Yet when we assessed plausible glioma-related variables such as smoking history and years of education, our 
results were not substantially altered.   
    Recall bias may be present since participants were asked to recall events that may have happened well over 
50 years ago.  We expect minimal bias because reproductive events are typically memorable, life changing 
events and previous studies have shown high levels of accuracy for menstrual history41,42,43,44,45,46 and reproductive 
history47,48,49,50, but we cannot rule out that index cases may be more motivated to recall exposures.  Agreement 
between proxy and case reported information has been previously shown to be reliable with parity but 
unreliable for other reproductive factors.51,52,53 Non-differential misclassification may have occurred with age at 
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menopause since the menopausal transition makes it difficult to precisely recall age at menopause.  Likewise, 
early menopausal women who typically have irregular menstrual periods might have mistakenly classified 
themselves as premenopausal.  It is difficult to predict how this may have affected results.  Misclassification 
could be differential if brain tumor development precedes a decline in circulating female hormones, regular 
occurrence of menstrual cycles, or ability to conceive.  Of more concern was the relatively large number of 
proxy respondents (nearly 21%) and their recall ability.  In this study, self-report cases and proxy cases were 
similar in reporting reproductive and hormone use histories as evidenced by non-significant case-case odds 
ratios.   
    Our study was limited to the assumption that menstrual cycles were regular throughout the entire 
reproductive period. In reality, twenty percent of cycles are 7 days longer or shorter than the expected length 
even in women who report that their cycles are regular.54   In addition, the first years and the last years of 
menstrual flow (perimenopausal transition) are characterized by a wide range of changes in menstrual patterns.  
Without more detailed information on menstrual cycle regularity, it is difficult to determine whether differential 
bias is present.  
    It is plausible reproductive factors are not correlated with hormones or they are too broad to capture the 
windows of relevant exposure when one hormone has more impact than another.  Exploring such a hypothesis 
would benefit from the additional consideration of testosterone, for which there is currently no good surrogate.  
Understanding the independent function of estrogen, progesterone, and testosterone in the nervous system is 
complex due to their apparent dual functions.  The same hormone may create a different response in males than 
females and this difference may vary from one brain region to another 4,55 adding to the complexity of which 
hormone would be largely responsible for the female advantage.  Nevertheless, future studies exploring more 
detailed information of menstrual cycles and testosterone levels using larger studies are likely to be areas of 
fertile research.    
    Overall, our study does not support an association between gliomas and reproductive or menstrual factors.  
Inverse risk estimates for the effects of oral contraceptive and postmenopausal hormone use were in agreement 
with prior studies, but consistent cumulative exposure-response relationships were generally not observed.    
Oral contraceptive use and postmenopausal hormone use combined may exert a greater beneficial effect than a 
history of using only one of the exogenous hormones.  Future epidemiologic studies could benefit from a more 
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detailed account of exogenous hormone use to confirm findings, but without a greater understanding of 
hormone function in the nervous system interpretation will remain limited.   
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F. Tables 
 
Table 3.1: Selected characteristics of glioma cases and controls comparing male participants to female 
participants in the San Francisco Adult Glioma Study  
 Male participants Female participants 
 Case (n=492) Control (n=470) Case (n=381) Control (n=394) 
    n          (%)    n          (%)    n          (%)    n          (%) 
 
Age (yrs) 
    
   20-44   145       (29)    136      (29)   106      (28)   115      (29) 
   45-54   110       (22)   102      (22)     53      (14)     67      (17) 
   55-64     89       (18)   100      (21)     69      (18)     64      (16) 
   65+   148       (30)   132      (28)   153      (40)   148      (38) 
   mean (sd)     54.2 (15.3)     54.2 (15.6)     56.9 (17.2)     55.8 (17.1) 
 chi square p = 0.65 chi square p =0.39 
     
Race     
  White   398       (81)   382      (81)   325      (85)   341       (87) 
  Black     18       (  4)    17      (  4)     17      (  4)     14       (  4) 
  Asian     21       (  4)     23      (  5)     12      (  3)     10       (  3) 
  Hispanic/Mexican     28       (  6)     29      (  6)     20      (  5)     20       (  5) 
  Other     27       (  5)     19      (  4)       7      (  2)       9       (  2) 
 chi square p = 0.85 chi square p = 0.93 
     
Smoking 100 cigarettes    
  Never   205       (43)   188      (41)   197      (52)   199       (51) 
  Past   203       (42)   201      (44)   139      (37)   136       (35) 
  Current     71       (15)     70      (15)     43      (11)     58       (15) 
  Missing     13            11           2            1       
 chi square p =0.85 chi square p = 0.36 
     
Education     
  High school or less   213       (43)    182     (39)   205     (54)   184       (47) 
  College   181       (37)    198     (42)   134     (35)   174       (44) 
  Graduate school/Professional     97       (20)      90     (19)     41     (11)     36       (  9) 
  Missing       1              0       1            0      
 chi square p =0.22 chi square p =0.04 
     
Proxy   
 No   302       (61)   468     (99)   222      (58)    392     (99) 
 Yes   190       (39)       2     (  1)   159      (42)       2      (  1) 
 chi square p <0.01 chi square p <0.01 
     
Histologic Tumor Type   
Glioblastoma   292       (59)    228      (60)  
Astrocytoma     80       (16)      77      (20)  
Oligodendroglioma/ 
Oligoastrocytoma    
    89       (18)      60      (16)  
Other*     31       (  6)      16      (  4)  
     
Numbers do not always total to 100% due to rounding  
*other=ependymoma, juvenile pilocytic, astrocytoma, medulloblastoma, gangliogliomas, and not specified 
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Table 3.2: Frequencies and adjusted odds ratios (95% CI) of reproductive factors among glioma cases and 
controls, and restricted to self-reporting respondents  
 Cases    
Reproductive 
factors 
All females 
(n=381) 
Self-reporting  
(n = 222) 
Controls 
(n=394)τ 
OR (95% CI)Ψ OR (95% CI)Ψ  
Parity       
   Never 
   Ever 
   Missing 
     82   (22) 
   299   (78)  
       0    
     64   (29) 
   158   (71) 
       0    
     84   (21) 
   310   (79) 
       0    
1.00 (ref) 
0.93 (0.64-1.33) 
1.00 (ref) 
0.87 (0.58-1.30) 
Children      
   None 
   1 
   2 
   3+  
     82   (22) 
     65   (17) 
   112   (29) 
   122   (32) 
     64   (29) 
     35   (22) 
     62   (39) 
     61   (39) 
     84   (21) 
     80   (26) 
   109   (35) 
   121   (39) 
   1.00 (ref) 
   0.79 (0.50-1.25) 
   1.01 (0.67-1.52) 
   0.95 (0.62-1.46) 
   1.00 (ref) 
   0.70 (0.41-1.19) 
   0.90 (0.56-1.43) 
   1.02 (0.62-1.68)     
Gravidity       
   Never 
   Ever 
   Missing 
   145   (78) 
     42   (22) 
     16    
     76   (79) 
     20   (21) 
       8    
   143   (69) 
     64   (31) 
       2    
   1.00 (ref) 
   0.62 (0.39-0.98) 
   1.00 (ref) 
   0.70 (0.39-1.28) 
Age at first birth      
   Nulliparous 
   ≤20 years old 
   20-25 years old 
   26-30 years old 
   30+ years old 
   Missing 
     82   (22) 
     76   (20) 
   109   (29) 
     64   (17) 
     48   (13) 
       2    
     64   (29) 
     40   (18) 
     50   (23) 
     42   (19) 
     25   (11) 
       1    
     84   (21) 
     66   (17) 
   126   (41) 
     76   (32) 
     42   (11) 
       0   
   1.00 (ref) 
   1.11 (0.70-1.77) 
   0.83 (0.55-1.26) 
   0.82 (0.51-1.30) 
   1.10 (0.65-1.87) 
         
   1.00 (ref) 
   1.03 (0.60-1.76) 
   0.70 (0.43-1.13) 
   0.93 (0.55-1.56) 
   0.98 (0.53-1.81) 
       
Age at menarche 
   ≤11 years old 
   12-13 years old 
   ≥14 years old 
   Missing 
 
     62   (20) 
   165   (52) 
     88   (28) 
     66    
 
     45   (20) 
   117   (53) 
     60   (27) 
       0    
 
     72   (18) 
   216   (55) 
   102   (26) 
       4    
 
   1.13 (0.76-1.67) 
   1.00 (ref) 
   1.15 (0.81-1.63) 
 
   1.17 (0.75-1.82) 
   1.00 (ref) 
   1.18 (0.79-1.75) 
         
Age at menopause      
   <45 years old 
   45-50 years old 
   50+ years old 
   Missing        
     75   (35) 
     76   (36) 
     63   (29) 
     34    
     33   (32) 
     41   (40) 
     29   (28) 
       8    
     74   (31) 
     93   (39) 
     72   (30) 
       2    
   1.00 (ref) 
   0.83 (0.53-1.29) 
   0.92 (0.57-1.48) 
  
   1.00 (ref) 
   1.09 (0.62-1.92) 
   1.13 (0.60-2.11) 
     
Menopausal statusδ     
   Premenopausal 
   Postmenopausal 
   Natural  
   Surgical  
   Other 
   Missing 
   125   (34) 
   248   (66) 
   143   (58) 
     92   (37) 
     13    ( 5) 
       8   
   111   (50) 
   111   (50) 
     61   (55) 
     42   (38) 
       8   (  7) 
       0 
   153   (39) 
   241   (61) 
   157   (65) 
     80   (33) 
       3   (  1) 
       1  
   1.00 (ref) 
   1.54 (0.94-2.53) 
   1.26 (0.69-2.31) 
   1.35 (0.93-1.95) 
  
   1.00 (ref) 
   1.57 (0.89-2.76) 
   1.40 (0.70-2.82) 
   1.38 (0.86-2.22) 
    
Menstruation yearsγ     
   <25 years 
   25-34 years 
   ≥35 years 
   Missing 
     79   (25) 
   118   (37) 
   118   (37) 
     66    
     68   (31) 
     85   (38) 
     69   (31) 
       0   (  0) 
   109   (28) 
   127   (33) 
   154   (39) 
       4    
   1.00 (ref) 
   1.48 (0.97-2.25) 
   1.35 (0.84-2.17) 
   1.00 (ref) 
   1.63 (1.03-2.58) 
   1.45 (0.84-2.49) 
        
 
γMenstruation years = menopausal age  menarche age. Menstruation years was linear in logit but categorized here for demonstration. 
δ Eight women self-reported having a menstrual period, but taking menopausal hormones. These 8 (1.94%) were classified as premenopausal since natural hormones were hypothesized to have a stronger effect than 
exogenous hormones.  Given the small number of women in this group, estimates are not expected to be impacted by possible misclassification.  Twelve postmenopausal women reported both natural and surgical 
menopause.  Eleven were classified as natural menopause since surgical menopause occurred after natural menopause. 
Ψ Adjusted for age (continuous) and race (binary) 
τ Two controls were proxies and were accounted for in the adjusted OR for self-reporting respondents 
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Table 3.3:  Adjusted odds ratios (95% CI) for interaction between age at menarche and menopausal status and 
time at menopausal onset and gliomas, and restricted to self-report respondents 
 Self-report premenopausal women  Self-report postmenopausal women 
 
 
 Case/Control OR (95% CI)  Case/control OR (95% CI)   
Age at 
menarche 
      
   ≤ 11 years 25/27 1.62 (0.85-3.06)  20/  45 1.55 (0.54-4.44)  
   12-13 years 56/97 1.00 (ref)  61/118 2.67 (1.25-5.73)  
    ≥14 years 30/29 1.77 (0.96-3.25)  30/  73 0.94 (0.37-2.39)  
       
 Self-report early menopause (<50 
years)ω 
 Self-report menopause age 50 or older ω  
Age at 
menarche 
Case/Control OR (95% CI)  Case/control OR (95% CI)   
   ≤ 11 years 13/22 0.64 (0.23-1.77)    7/23 1.08 (0.43-2.71)  
   12-13 years 34/71 1.00 (ref)  20/47 0.84 (0.41-1.71)  
    ≥14 years 15/40 1.04 (0.46-2.36)  15/32 0.74 (0.32-1.72)  
       
 All premenopausal women 
 
 All postmenopausal women  
 Case/Control OR (95% CI)  Case/control OR (95% CI)   
Age at 
menarche 
      
   ≤ 11 years 26/27 1.50 (0.80-2.82)    36/  45 2.09 (0.82-5.29)  
   12-13 years 62/97 1.00 (ref)  102/119 2.14 (1.08-4.27)  
    ≥14 years 34/29 1.82 (1.01-3.30)    54/  73 1.29 (0.56-2.97)  
       
 All females with early onset of 
menopause (<50 years) ω 
 All females with menopausal onset age 50 
or older ω 
 
Age at 
menarche 
Case/Control OR (95% CI)  Case/control OR (95% CI)   
   ≤ 11 years 23/22 0.66 (0.29-1.51)  12/23 1.18 (0.55-2.56)  
   12-13 years 53/72 1.00 (ref)  38/47 0.82 (0.45-1.47)  
    ≥14 years 25/40 1.04 (0.53-2.04)  27/32 0.73 (0.37-1.43)  
       
adjusted for age (continuous) and race (binary)  
ω among postmenopausal women 
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Table 3.4: Frequencies and adjusted odds ratios (95% CI) of exogenous hormone use among glioma cases 
and controls, and restricted to self-reporting respondents 
 Cases    
Exogenous 
hormone factors 
All females 
(n=381) 
Self-reporting 
respondents  
(n = 222) 
Controls 
(n=394)τ 
   
OR (95% CI)Ψ OR (95% CI)Ψ  
OC use       
   Never 
   Ever 
   Missing 
   188   (52) 
   176   (48)  
     17    
     84   (38) 
   138   (62) 
       0    
   166   (42) 
   227   (58) 
       1    
1.00 (ref) 
0.60 (0.42-0.86) 
   1.00 (ref) 
0.73 (0.49-1.10) 
OC use      
   Never    188 (52)     84 (38)    166 (42) 1.00 (ref)    1.00 (ref) 
   Former    162 (45)   127 (57)    194 (49) 0.62 (0.43-0.89) 0.77 (0.51-1.16) 
   Current      14 (  4)     11 (  5)      33 (  8) 0.28 (0.13-0.59) 0.26 (0.11-0.59) 
   Missing      17        0        1   
OC duration        
   Never 
   < 1 year 
   1-4 years 
   5-9 years 
   ≥10 years 
   Missing 
   188   (53) 
     24   (  7) 
     68   (19) 
     41   (12) 
     34   (10) 
     26    
     84   (38) 
     23   (10) 
     56   (25) 
     32   (15) 
     25   (11) 
       2    
    166   (42) 
      46   (12) 
      68   (17) 
      51   (13) 
      62   (16) 
        1    
1.00 (ref) 
0.41 (0.23-0.72) 
0.78 (0.49-1.22) 
0.62 (0.37-1.04) 
0.43 (0.26-0.72) 
   p trend = 0.06δ 
1.00 (ref) 
0.62 (0.34-1.15) 
0.98 (0.60-1.61) 
0.70 (0.39-1.25) 
0.50 (0.28-0.89) 
  p trend = 0.05δ 
PHT use ω      
   Never 
   Ever 
   Missing 
   119   (51) 
   115   (49) 
     14    
     51   (46) 
     59   (54) 
       1    
     82   (34) 
   157   (66) 
       2    
1.00 (ref) 
0.49 (0.33-0.71) 
1.00 (ref) 
0.53 (0.33-0.86) 
PHT use ω      
  Never   119 (51)      51 (46)      82 (34) 1.00 (ref)    1.00 (ref) 
  Former     61 (26)      26 (24)      60 (25) 0.70 (0.44-1.11) 0.73 (0.40-1.32) 
  Current     54 (23)      33 (30)      97 (41) 0.35 (0.22-0.55) 0.43 (0.24-0.74) 
   Missing     14        1        2   
PHT durationω      
  Never 
   < 1 year 
   1-4 years 
   5-9 years 
   ≥10 years 
   Missing 
   119   (54) 
       7   (  3) 
     35   (16) 
     12   (  5) 
     48   (22) 
     27    
     51   (47) 
       4   (  4) 
     20   (19) 
       9   (  8) 
     24   (22) 
       3    
      82  (34) 
      21  (  9) 
      45  (19) 
      21  (  9) 
      69  (29) 
        3   
1.00 (ref) 
0.23 (0.09-0.56) 
0.50 (0.29-0.85) 
0.74 (0.32-1.72) 
1.29 (0.58-2.89) 
   p trend = 0.60δ 
1.00 (ref) 
0.29 (0.09-0.92) 
0.53 (0.27-1.03) 
1.12 (0.43-2.94) 
0.92 (0.37-2.33) 
  p trend = 0.54δ 
Cumulative 
exposure γ 
   ≤312 months 
   313407 months 
   408503 months 
   ≥504 months 
   Missing 
 
     88   (28) 
     63  (20) 
     98   (31) 
     66   (21) 
     66   
 
     76   (34) 
     47   (21) 
     67   (30) 
     32   (14) 
       0    
 
   101   (26) 
     81   (21) 
   107   (27) 
   101   (26) 
      4     
 
1.00 (ref) 
0.97 (0.60-1.58) 
1.20 (0.73-1.99) 
0.88 (0.50-1.55) 
   p trend = 0.13 
 
1.00 (ref) 
1.16 (0.68-1.96) 
1.52 (0.86-2.67) 
0.88 (0.45-1.73) 
     p trend =0.23 
      
γ  Cumulative exposure = menopausal age  menarche age + duration of postmenopausal hormone use.   
ω Among postmenopausal women 
Ψ Adjusted minimally for age (continuous) and race (binary) 
τ Two controls were proxies and were accounted for in the adjusted OR for self-reporting respondents 
δ P value for Wald statistic among ever users only 
NOTE: OC = oral contraceptives   PHT = postmenopausal hormone therapy 
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Table 3.5:  Adjusted odds ratios (95% CI) for interaction between oral contraceptive use and 
postmenopausal hormone use and gliomas among postmenopausal women, and restricted to self-reporting 
respondents 
Oral 
contraceptive 
use 
among self-
report females 
Never postmenopausal hormone use 
among self-report females 
 Ever postmenopausal hormone use 
among self-report females 
 Case/control     ORa  (95% CI)  Case/control     ORa  (95% CI) 
Never   30/55 1.00 (ref)    31/86 0.60 (0.32-1.12)  
Ever   21/26 0.90 (0.38-2.10)    28/70 0.45 (0.21-0.99) 
      
Oral 
contraceptive 
use 
among all 
females 
Never postmenopausal hormone use 
among all females 
 
Ever postmenopausal hormone use 
among all females 
 Case/control     ORa  (95% CI)  Case/control     ORa  (95% CI) 
Never   85/56 1.00 (ref)  65/86 0.48 (0.30-0.77) 
Ever   31/26 0.55 (0.26-1.17)  44/71 0.34 (0.18-0.64) 
a adjusted for frequency matched factors age (continuous) and race (binary) 
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CHAPTER IV: DNA REPAIR POLYMORPHISMS XRCC1 ARG399GLN, MGMT LEU84PHE, AND 
MGMT ILE143VAL AND GLIOMAS 
 
A.  Abstract 
 
    Variants in DNA repair genes might influence the cells ability to repair DNA mutations.  X-ray cross 
complementing group 1 (XRCC1) and O6-methylguanineDNA methyltransferase (MGMT) are pivotal repair 
genes focused on repairing lesions due to ionizing radiation, alkylating agents, and oxidative DNA damage, risk 
factors previously linked to gliomas.  Using the population based San Francisco Adult Glioma study, we 
evaluated associations between XRCC1 Arg399Gln, MGMT Leu84Phe, and MGMT Ile143Val polymorphisms 
and gliomas.  Unconditional logistic regression models adjusting for frequency matched factors age, 
race/ethnicity, and gender were used to assess genotype data from white cases (n=441 to 453) and controls 
(n=487 to 526).  We found no evidence of an association between XRCC1 genotypes and glioma. The adjusted 
odds ratio (OR) of the XRCC1 399Gln variant (Arg or Gln/Gln versus Arg/Arg) among whites was 0.96 (95% 
confidence interval (CI), 0.72-1.28).  We observed a weak positive association for the MGMT Leu84Phe 
polymorphism (Leu or Phe/Phe versus Leu/Leu: adjusted OR = 1.26; CI, 0.90-1.75) and the MGMT Ile143Val 
polymorphism (Ile or Val/Val versus Ile/Ile: adjusted OR = 1.20; CI, 0.85-1.71). Among variant carriers, 
association with 84Phe were more pronounced among males (adjusted OR = 1.75; CI,1.12-2.74) and non-
glioblastoma cases (adjusted OR = 1.54; CI, 1.02-2.34), but estimates were imprecise.  DNA repair 
polymorphisms did not notably modify adjusted odds ratios for the smoking-glioma association.  Our results 
suggest that XRCC1 Arg399Gln polymorphisms are not associated with glioma susceptibility, but MGMT 
Leu84Phe polymorphisms may play a role in the etiology or development of non-glioblastomas.  Future studies 
using a larger more diverse study population and a more comprehensive measure of genetic variation would 
help clarify the role of repair genotypes in gliomagenesis. 
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B.  Introduction 
    Gliomas are generally thought to be caused by a combination of environmental and genetic exposures.  
Normally, DNA repair mechanisms, including direct reversal, base excision repair pathway (BER), nucleotide 
excision repair pathway (NER), mismatch repair (MMR), and double strand break repair, are responsible for 
repairing DNA damage that may lead to mutations.  Variants in DNA repair genes may modify cancer 
susceptibility by influencing the cells ability to prevent mutations.1  Polymorphisms in several genes important 
to DNA repair have been associated with cancer risk, 2,3 but data on glioma risk are limited.   
    Variants of DNA repair genes in three repair pathways (direct reversal, NER, BER) have previously been 
associated with gliomas. 4,5,6,7,8,9  We hypothesized that the XRCC1 Arg399Gln polymorphism and two MGMT 
polymorphisms, MGMT Leu84Phe and MGMT Ile143Val are associated with gliomas.  X-ray repair cross 
complementing group 1 (XRCC1), a critical component of the BER pathway, is located on a region of the 
chromosome 19 that is altered in 40% of gliomas 10,11 and is in close proximity to DNA repair genes ERCC1 and 
ERCC2 that have been associated with gliomas.  XRCC1 interacts with DNA polymerase B and DNA ligase III 
to repair damage caused by tobacco smoke, oxygen radicals, and ionizing radiation.  High dose ionizing 
radiation is an established risk factor for gliomas 12,13 and oxygen radicals are also a suspected but unproven risk 
factor.14,15  Tobacco smoke contains known neurocarcinogens, but most studies have not found an association 
between smoking and gliomas.16,17  Although the XRCC1 399Gln variant has not been directly associated with 
gliomas, it is known to interact with other base excision repair enzymes such as apurinic/apyrimidinic 
endonuclease 1 18,19,20  whose activity has been shown to increase in adult gliomas.21   
    MGMT is a pivotal gene in direct repair of damage caused by alkylating mutagens, also putative risk factors 
of gliomas.16,22 Once induced, MGMT directly and specifically removes alkyl DNA adducts at the O6 position of 
guanine by transferring the alkyl group to one of its own cysteine residues preventing nucleotide transition.  
MGMT is located in chromosome 10q26 where heterozygous deletion is often observed in glioblastoma (GBM) 
patients.23  Two tumor suppressor genes, PTEN and DMBT1, are located in the same region (10q23 and 10q25, 
respectively) making this chromosomal region of potential interest. At present, the functional signficiance of 
these DNA repair polymorphisms is uncertain; however, there is some evidence that the MGMT 84Phe variant 
increases repair activity and the expression of the MGMT protein.24,25     
 96
    We evaluated whether XRCC1 and MGMT polymorphisms were associated with gliomas using genotype 
data from participants in the large San Francisco Adult Glioma Study, and conducted further analyses of the 
joint effects of these DNA repair variants and cigarette smoking.  
C. Materials and Methods 
1.  Study participants 
    Details of this population-based case-control population have been described previously. 26,27,28,29 Eligible cases 
included all adults newly diagnosed with glioma (International Classification of Disease for Oncology, 
morphology codes 9380-9481) in six San Francisco Bay Area counties (Alameda, Contra Costa, Marin, San 
Mateo, San Francisco, and Santa Clara) from August 1991 to April 1994 (Series 1) and from May 1997 to 
August 1999 (Series 2).  Cases were identified using the Northern California Cancer Centers Rapid Case 
Ascertainment program as previously described. 9,11,12  Controls ascertained through random digit dialing were 
frequency matched to cases by age, race/ethnicity, and gender.   
2. Exposure assessment   
    In the parent study, trained interviewers administered a comprehensive questionnaire to participants (or their 
proxy) to capture a broad array of information on potential risk factors.  Cigarette smoking was selected a priori 
for examination of interaction with DNA repair genotypes.  Ever smokers were defined as those subjects that 
reported smoking more than 100 cigarettes over their lifetime.  Cigarette smokers were asked to recall the age 
they started smoking, the number of cigarettes smoked per day, the number of years smoked, and whether the 
cigarettes were filtered or nonfiltered.  In the analysis, cigarette smoking was represented as ever/never, 
current/former/never, total years smoked cigarettes, and total pack-years.  Category boundaries for continuous 
variables were determined by univariate distributions among controls. Other forms of tobacco (such as cigars 
and pipes) were not assessed in this analysis, nor was second-hand smoke exposure.   
    Blood specimen collection began partway through Series 1 when funding for specimen collection was 
obtained.  Thus, we obtained a blood sample from only 186 cases (39% of 476 confirmed cases) and 170 
controls (37% of 462 controls).  The majority of Series 2 participants submitted a blood or buccal sample (71% 
of 401 cases and 94% of 402 controls).  XRCC1 genotyping was successfully conducted for 441 cases (51% of 
873 participating cases) and 487 controls (56% of 864 participating controls).  XRCC1 genotyping failed for a 
total of 14 subjects (5 cases, 1.12%; 9 controls, 1.81%).  MGMT genotyping was successfully conducted for 467 
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cases (53.5% of 873 participating cases) and 542 controls (62.7% of 864 controls).  Genotyping failed for 
Leu84Phe in 14 cases (3.0%) and 16 controls (2.95%) and failed for Ile143Val in 26 (5.6%) cases and 34 
controls (6.3%).   
3.  Genotyping methods   
    Genomic DNA was extracted from whole blood using the QIAamp Blood Kit (QIAGEN, Hilden, Germany).  
XRCC1 genotype was assayed using a polymerase chain reaction (PCR) followed by restriction fragment length 
polymorphism (RFLP). The XRCC1 Arg399Gln polymorphism was determined using a 50:l reaction volume 
containing 0.3 ng of DNA, 0.2 mM of each primer (sense:5CCAAGTACAGCCAGGTCCTA-3 and antisense: 
5-AGTCTGACTCCCCTCCGGAT-3), 1.25 units of taq DNA polymerase (Perkin-Elmer, Branchburg, NJ), 
1.25 mM of dNTP, 10mM Tris-HCl, pH 8.3 (at 25 C), 50 mM KCl, 1.5 mM MgCl2, and 0.001% (W/V) gelatin.  
PCR cycle conditions were: holding at 94 C for 5 minutes; then 35 cycles of denaturation at 94 C, annealing at 
60C, and extension at 72 C for 1 minute. After amplification, PCR products were digested with MspI (New 
England Biolabs), as described by the supplier. Each digested sample was electrophoresed in agarose gel in 
TBE bufffer. The gel then was stained with ethidium bromide, visualized on a transilluminator under UV light, 
and photographed.    
    MGMT genotypes were assayed using an allelic discrimination 5-nuclease assay (Taqman) on the ABI 
PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) in 96 well format.  Taqman 
primers and probes were designed using the Primer Oligo Design Software v2.0 (Applied Biosystems).  Primers 
for the amplification of MGMT Leu84Phe were f- CCCGAGGCTATCGAAGAGTTC and r-
CCGACCTTGCTGGAAAACG, and probes were vic-ATGGTGAAGAGCCGG-NFQ and fam-
ATGGTGAAAAGCCGG-NFQ.  Primers for the amplification of MGMT Ile143Val were f-
TGCCCCCCTGTCTTCCA and r-GCTGCTGCAGACCACTCT, and probes were vic-
CCCATCCTCATCCCGT-NFQ and fam-CCCATCCTCGTCCCGT-NFQ.  Laboratory personnel were blinded 
to case-control status and both negative and positive controls (including every 10th sample as a blinded 
duplicate) were included.   
4.  Data Analysis   
    Baseline characteristics of cases and controls were compared using the chi-square statistic for categorical 
variables and Students t-test for continuous variables.  Genotype frequencies among cases and controls were 
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compared with expectation according to the Hardy-Weinberg equilibrium model.  Odds ratios (OR) and 95% 
confidence intervals (95% CI) for the main effects of each DNA repair genotype were estimated using 
unconditional logistic regression models.  The more common genotype (XRCC1 Arg399Arg, MGMT 
Leu84Leu, and MGMT Ile143Ile) was designated as the referent in both dominant and recessive models.  
Confounders were defined as covariates that changed the estimated exposure OR by greater than 10% when 
removed from the model.  Final models were adjusted for frequency matched factors age and sex.  The joint 
effect of smoking and each genotype was evaluated on the multiplicative scale using the likelihood ratio test (α= 
0.20).  To further quantify risk difference (additive scale) effect modification, we compared the observed OR of 
the joint effect for the doubly exposed (variant allele carrier and greater exposure to smoking) to the expected 
joint OR assuming additive risks. Gene-gene interactions were assessed similarly with the variant allele for both 
genotypes defined as doubly exposed.  Additional analyses were conducted stratifying by histologic subtype 
(glioblastoma, non-glioblastoma), gender, race/ethnicity (white, non-white), and age group (<45, ≥45-54, ≥55-
64, 65+).  Nearly half (46% of 312) of glioblastoma cases were missing genotype information, usually because 
of death.  To evaluate whether missingness would bias case-subtype results, we performed a sensitivity analyses 
under reasonable hypothetical scenarios assuming that missing cases were more likely to have the variant 
genotype or non-variant genotype.  The exclusion of these participants did not appreciably alter odds ratio 
estimates, even when considering the highly unlikely scenario that the distribution of genotypes among the non-
genotyped cases was the same as that among the observed cases  
D.  Results 
    Genotype data were available for 461 cases (52% of 873 parent study cases) and 558 controls (65% of 864 
parent study controls).   The distribution of race/ethnicity and gender among those genotyped were comparable 
between cases and controls. (Table 4.1)  The mean age for genotyped cases was 50.9 years and 56.1 years for 
genotyped controls (p < 0.01).  Cases who were not genotyped tended to be older (mean age 60.1 years vs. 50.9 
years) and more likely to have glioblastoma histology (70% vs. 50%).  Because genotype frequencies and odds 
ratios were similar in controls between series (Pearsons chi square p value for XRCC1 399 = 0.92, for MGMT 
84 = 0.90, for MGMT 143 = 0.54) data from both series were combined.  Proxy interviews were necessary for 
13% of cases with genotyping data who were incapacitated or deceased. Unless otherwise indicated, analyses 
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were restricted to whites due to limited power to estimate association separately for non-whites (15% of 928 
genotyped participants) and to facilitate comparison of results to previous studies.    
1. XRCC1 Arg399Gln polymorphism and gliomas  
    The majority of whites with genotype data were carriers of at least one 399Gln allele (57% of cases and 58% 
of controls).  Among non-whites, 57% of cases and 43% of controls had at least one 399Gln allele.  The 
frequency of the Gln allele was nearly identical between white cases and controls (0.36 and 0.35, respectively, 
Table 4.2) and between all cases and controls combined (0.34 for both cases and controls).  Genotype 
frequencies among cases and controls were consistent with those expected from the Hardy-Weinberg 
equilibrium model.  Among whites, 15% of cases versus 12% of controls had the homozygous XRCC1 Gln/Gln 
genotype, resulting in a slightly elevated odds ratio of 1.14 (95% CI: 0.73-1.79) relative to the Arg/Arg 
genotype; however, the combined Arg/Gln, Gln/Gln genotype OR was close to the null (adjusted OR = 0.96, 
95% CI: 0.72-1.28).  There was no clear pattern of association when stratified by age at diagnosis or histologic 
subtype.   
2. MGMT Leu84Phe and MGMT Ile143Val polymorphisms and gliomas 
    The MGMT 84Phe allele frequency among white cases and controls was 0.13 and 0.11, respectively (Table 
4.2), while MGMT 143Val allele frequencies were 0.11 for cases and 0.10 for controls. Distributions of both 
MGMT polymorphisms were consistent with Hardy-Weinberg expectations for cases and controls.  We 
observed a small positive association between gliomas and MGMT 84Phe (adjusted OR for combined Leu/Phe 
or Phe/Phe versus Leu/Leu: 1.26, 95% CI: 0.90-1.75) and MGMT 143Val (adjusted OR for combined Ile/Val or 
Val/Val versus Ile/Ile: 1.20, 95% CI: 0.85-1.71).  The positive association between the 84Phe variant and 
glioma appeared to be specific to males (adjusted OR for males = 1.75, 95% CI: 1.12-2.74; for females = 0.82, 
95% CI: 0.49-1.38, Table 4.3) and non-glioblastoma cases (adjusted OR for non-glioblastomas: 1.54, 95% CI: 
1.02-2.34; for glioblastomas: 1.02, 95% CI: 0.66-1.56).   
3. Smoking-repair gene interaction  
    There was little evidence of odds ratio modification between XRCC1 399Gln and smoking in relation to 
gliomas (never smokers: adjusted OR = 1.20, 95% CI: 0.78-1.83; ever smokers: OR = 0.98, 95% CI: 0.66-1.47, 
LRT p value = 0.20, Table 4.4).  The joint effect of the variant genotype (Arg/Gln or Gln/Gln) and ever 
smoking was only slightly less than multiplicative and additive (observed OR = 0.98; expected assuming no OR 
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modification = 1.5; expected OR assuming no risk difference modification = 1.4).  Observed odds ratios for the 
combined XRCC1 variant genotype and heavier smoking (≥20 years: adjusted OR = 1.03, 95% CI: 0.65-1.64; 
≥15 pack years: adjusted OR = 1.15, 95% CI: 0.69-1.90) were less than expected assuming additive risks 
(expected ORcigyears = 1.6; expected ORpackyears = 1.7).  When restricted to males (data not shown), the joint odds 
ratio between ever smoking males with the Gln399 genotype relative to never smokers with the 399 Arg/Arg 
genotype (adjusted OR = 1.44 , 95% CI: 0.82-2.53; LRT p value = 0.03) was significantly different from 
multiplicative expectations, but stronger odds ratios were observed among those singly exposed (ever smoking 
and non-variant genotype: adjusted OR = 1.99 (95% CI: 1.08-3.69); never smoking and variant genotype: 
adjusted OR = 1.84 (95% CI: 1.00-3.38)) caution should be used in interpreting these results given the 
imprecision of the estimates.  Evaluation of MGMT polymorphisms demonstrated no suggestion of effect 
measure modification (OR or risk difference modification) by smoking (data not shown). 
4.  Gene-gene interaction  
    We did not find polymorphisms of ERCC1 (C8092A) and ERCC2 (R156R, K751Q) modified the effect of 
XRCC1 399Gln and gliomas on the additive and multiplicative scales. (Table 4.5)   
E.  Discussion 
    Current knowledge of DNA damage and repair processes largely derive from studies of non-neuronal cells, 
thus there is limited information regarding DNA repair in the brain.  It was initially thought that brain cells (e.g. 
neurons, oligodendrocytes, astrocytes, and perhaps non-glial cells) curtailed DNA repair.30  Recent studies 
found that the brain retains neural stem cells that may partially or incorrectly differentiate leading to tumor 
formation.31,32,33  Additionally, astrocytes in the adult brain can dedifferentiate back into immature glial cells with 
the ability to proliferate.  Whether progenitor or differentiated neuronal cells are targets of neoplastic 
transformation is unknown, but both are likely to have different repair processes.  There is widespread 
agreement that DNA repair systems are required to maintain the central nervous system.  Xeroderma 
pigmentosum is perhaps the best example of this as premature death of neuronal cells occurs due to inherited 
defects in DNA repair mechanisms.  There is evidence that defects in DNA repair mechanisms my play a role in 
survival, prognosis, or carcinogenesis.  In a study of GBM cell lines with different radiosensitivities, DNA 
repair genes were notably upregulated,34 suggesting neuronal cells are capable of DNA repair.  This finding is 
consistent with the increased activity of DNA repair proteins MGMT, MPG, and APE1 reported in gliomas.7, 21, 22, 
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34  MGMT is a major determinant of chemotherapy resistance in gliomas and may partially explain the potential 
significance of repair mechanisms.35,36 
    In this population-based case-control study, none of the polymorphic variants of selected DNA repair 
polymorphisms XRCC1 Arg399Gln, MGMT Leu84Phe, and MGMT Ile143Val were found to be significantly 
associated with glioma incidence.  A positive association with non-glioblastomas but not glioblastomas was 
observed for carriers of the MGMT 84Phe variant.  This may be explained by known etiologic differences 
between histologic subtypes.37  However, results may have been also influenced by missing data from non-
genotyped cases.38  In our analysis, we omitted participants that did not have genotype information which 
included more cases than controls (e.g. missingness was not random).  Consequently, odds ratios from our case-
subtype specific analysis may be biased since most of the non-genotyped cases were the more fatal tumor 
subtype (GBM).  This is not likely to affect estimates in this study as a subsequent analysis using this dataset 
did not find a relationship of survival by genotype.  We further performed a sensitivity analysis under different 
scenarios assuming missing GBM cases were more likely to have the variant genotype or non-variant genotype.  
Our results suggest that although there is potential for tremendous loss of information, excluding missing GBM 
cases in subtype analysis from missing cases did not notably bias estimates.  The significantly increased odds 
ratio among males for the 84Phe variant is intriguing, but likely explained by the differences in the sex ratio 
between GBM and non-GBM in our study population (male:female ratio: 1.6 and 1.2, respectively).   
    To the best of our knowledge, only one other study previously investigated the association between XRCC1 
Arg399Gln polymorphism and gliomas.8  Results from the Wang et al. hospital based case control study are 
consistent with our findings of similar genotypic distribution between cases and controls.  The previously 
reported positive association between the MGMT Leu84Phe genotype and glioblastomas among Asians (OR = 
2.91, 95% CI: 1.19-7.08) was not observed in this study population.7  This may be due to the differing ethnic 
composition between the studies or the smaller sample size of the previous study (n=22 glioblastomas).  Our 
study of 189 glioblastoma cases found a more precise estimate smaller in magnitude. 
    Smoke contains compounds (e.g. benzene, aromatic amines, and polycyclic aromatic hydrocarbons) that have 
indisputably been found to induce tumors39 and generate reactive oxygen species (ROS) capable of inducing 
double strand breaks in DNA.40, 41  The brain is an oxygen rich organ inherently sensitive to ROS.  Experimental 
and epidemiologic evidence have provided evidence supporting oxygen radicals as a risk factor for  
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gliomas.14,42,43, ,44  However, epidemiologic studies have failed to find a consistent association between gliomas 
and smoking.  The blood brain barrier prevents most carcinogenic components of tobacco smoke from reaching 
brain cells,  some tobacco-related genotoxins may (e.g. via the intranasal pathway) or otherwise penetrate the 
blood brain barrier (e.g. N-nitroso compounds, another constituent of tobacco smoke).  We found evidence of a 
less than multiplicative or additive joint effect between selected DNA repair genotypes and ever smoking.  Lack 
of variation between stratum-specific odds ratios when assessing cigarette years and total pack years were 
consistent with multiplicative joint effects, but without more cases it is difficult to determine whether the effect 
of polymorphisms vary across exposure levels.  Our observations of stronger associations between smoking and 
gliomas among male carriers of the XRCC1 nonvariant (arg/arg) genotype was contrary to our  prior 
hypothesis, we expected ORs for smoking exposure to be significantly elevated among 399 variant carriers.  A 
possible interpretation of this could be that damaged cells may have a higher chance of undergoing apoptosis 
instead of base excision repair; or because heavier smokers tended to be older, the lower risk for variant alleles 
in heavy smokers may reflect prolonged survival.   
    A substantial limitation of this study was that we looked at only a few base changes in candidate genes 
XRCC1 and MGMT.  Considering the hundreds of genes involved in DNA repair, the potential linkage 
disequilibrium with other variants in the genes evaluated or in neighboring genes, the lack of environmental risk 
factors strongly associated with gliomas, and the lack of denser SNP data and haplotype estimation, we have not 
fully measured the sources of genetic variation tat may influence DNA repair.  In addition, the low frequency of 
variant alleles makes it difficult to detect subtle differences associated with low penetrant repair genes.   
    This is the first population based study to investigate XRCC1 Arg399Gln and MGMT Ile143Val 
polymorphisms in association with gliomas.  Our results indicate XRCC1 399Gln and MGMT 143Val variants 
are not associated with increased glioma incidence.  The positive association of the MGMT 84Phe variant in 
non-glioblastomas is difficult to interpret given the small number of exposed cases and the missing genotype 
data for fatal tumor cases which are more likely to be glioblastomas.  Future studies may benefit from more 
comprehensive SNP and haplotype data from larger, more ethnically diverse sample populations to help 
understand repair mechanisms in gliomas.  
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F.  Tables 
Table 4.1  Selected characteristics of glioma cases and controls genotyped for XRCC1 399, MGMT 84, and 
MGMT 143 polymorphisms 
 Parent Study  XRCC1 399  MGMT 84  MGMT 143 
 Cases 
(n=873) 
% 
Controls 
(n=864) 
% 
 Cases 
(n=441) 
% 
Controls 
(n=487) 
% 
 Cases 
(n=453) 
% 
Controls 
(n=526) 
% 
 Cases 
(n=441) 
% 
Controls 
(n=508) 
% 
Age (years) 
   20-44 
   45-54 
   55-64 
      65+ 
 
      29 
      19 
      18 
      34 
 
        29 
        20 
        19 
        32 
p=0.58 
  
      36 
      23 
      20 
      21 
 
        25 
        21 
        20 
        34 
p<0.01 
  
      36 
      23 
      20   
      21 
 
        26 
        21 
        20 
        33 
p=<0.01 
  
      37 
      23 
      19     
      21 
 
      26 
      21 
      20 
      33 
p<0.01 
Gender 
     Male 
    Female 
      
 
      56 
      44 
 
        54 
        46 
p=0.41 
  
      59 
      41 
 
        53 
        47 
p=0.10 
  
      59 
      41 
 
        54 
        46 
p=0.14 
  
      58 
      42 
 
      54 
      46 
p=0.20 
Race 
     White 
     Black 
     Other 
 
 
      83 
        4 
      13 
 
        84 
          4 
        13 
p=0.86 
 
  
      83 
        4 
      13 
 
        88 
          3 
        10 
p=0.13 
 
  
      84 
        4 
      12 
 
 
        87 
          3 
        10 
p=0.27 
 
  
      84 
        4 
      13 
 
      87 
        3 
      10 
p=0.39 
Smoke*  
     Never 
     Past 
    Current 
  
 
    47 
    40 
    13 
 
        45 
        40 
        15 
p=0.54 
  
      50 
      38 
      12 
 
 
        46 
        40 
        14 
p=0.18 
  
      51 
      38 
      12 
 
        47 
        39 
        14 
p=0.18 
  
      51 
      38 
      12 
 
      45 
      40 
      14 
p=0.09 
Tumor 
type 
     GBM 
     Astro 
     Oligo 
        Other     
 
    60 
    17 
    17 
      6 
   
      50 
      18 
      23 
        9 
   
      49 
      18 
      23 
        9 
   
      49 
      19 
      24 
        8 
 
NOTE:  Nine (2%) controls and 5 (1%) cases for XRCC1; 14 (3%) cases and 16 (3%) controls for MGMT84; and 26 (6%) cases and 34 
(6%) controls for MGMT143 were unsuccessfully genotyped  they are not included in case and control counts. 
Abbreviations:  GBM = glioblastoma; Astro = astrocytoma; Oligo = tumor with an oligo component (i.e. oligodendroglioma or 
oligoastrocytoma); other = ependymoma, juvenile pilocytic astrocytoma, medulloblastoma, gangliogliomas 
P values refer to chi-square tests 
*Smoked 100 cigarettes 
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Table 4.2    Frequencies and odds ratios (95% CI) for XRCC1 Arg399Gln, MGMT Leu84Phe, and MGMT 
Ile143Val polymorphisms associated with gliomas among whites 
 Cases  
    n        (%) 
 Controls  
     n       (%) 
OR (95% CI) Adjusted 
OR (95% CI) a  
XRCC1_399 
Arg/Arg 
Arg/Gln 
Gln/Gln 
Arg/Gln + Gln/Gln 
  Gln allele frequency 
 
158     (43) 
155     (42) 
  53     (15) 
208     (57) 
      0.36 
  
180    (42) 
196    (46) 
51  (12) 
247    (58) 
      0.35 
 
1.00  (ref) 
0.90 (0.67-1.22) 
1.18 (0.76-1.84) 
0.96 (0.72-1.27) 
 
1.00  (ref) 
0.91 (0.67-1.24) 
1.14 (0.73-1.79) 
0.96 (0.72-1.28) 
MGMT Leu84Phe 
Leu/Leu 
Leu/Phe 
Phe/Phe 
Leu/Phe + Phe/Phe 
  Phe allele frequency 
 
289     (76) 
  84     (22) 
    6     (  2) 
  90     (24) 
      0.13 
  
   369    (80) 
     84    (18) 
       6    (  1) 
     90    (20) 
      0.11 
 
1.00 (ref) 
1.28  (0.91-1.79) 
1.28  (0.41-4.00) 
1.28  (0.92-1.78) 
 
1.00  (ref) 
1.25 (0.89-1.77) 
1.33 (0.42-4.22) 
1.26 (0.90-1.75) 
MGMT Ile143Val 
Ile/Ile 
Ile/Val 
Ile/Val + Val/Val 
  Val allele frequency 
 
291      (79) 
  76      (20) 
  78      (21) 
      0.11 
  
  359     (81) 
    75     (17) 
    82     (19) 
      0.10 
 
1.00 (ref) 
1.25  (0.88-1.78) 
1.17  (0.83-1.66) 
 
1.00 (ref) 
1.27 (0.89-1.82) 
1.20 (0.85-1.71) 
a  adjusted for frequency matched factors age (indicator) and sex 
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Table 4.3  Frequencies and odds ratios (95% CI) between MGMT Leu84Phe polymorphism and gliomas among 
whites, stratified by histologic subtype and gender 
 Glioblastoma  Non-glioblastoma  
 Case/control OR (95% CI)a  Case/control  OR (95% CI) a  
MGMT Leu84Phe       
   Leu/Leu    151/369 1.00 (ref)       138/369 1.00 (ref)  
   Leu/Phe      38/  84 1.09 (0.70-1.68)         46/  84 1.43 (0.93-2.20)  
   Leu/Phe + Phe/Phe      38/  90 1.02 (0.66-1.56)         52/  90 1.54 (1.02-2.34)  
  Phe allele frequency 0.10/ 0.11    0.15/ 0.11   
 Males  Females  
 Case/control OR (95% CI)b  Case/control  OR (95% CI) b  
MGMT Leu84Phe       
   Leu/Leu 156/198 1.00 (ref)       133/171 1.00 (ref)  
   Leu/Phe         58/  38 1.87 (1.18-2.98)         26/  46 0.74 (0.43-1.27)  
   Leu/Phe + Phe/Phe         61/  43 1.75 (1.12-2.74)         29/  47 0.82 (0.49-1.38)  
  Phe allele frequency   0.15 /0.10      0.10/0.11   
a adjusted for frequency matched factors age (indicator) and sex 
b adjusted for frequency matched factors age (indicator) 
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Table 4.4   Age-adjusted odds ratios (95% CI) for interaction between XRCC1 Arg399Gln polymorphism and 
smoking and gliomas among whites 
Smoking XRCC1 Arg/Arg  XRCC1 Arg/Gln or Gln/Gln 
 Case/control     ORa  (95% CI)  Case/control     ORa  (95% CI) 
Never 73/91 1.00 (ref)    99/106 1.20 (0.79-1.83)  
Ever 84/89 1.23 (0.80-1.92)  109/141 0.98 (0.66-1.47) 
      
Never 73/91 1.00 (ref)    99/106 1.20 (0.79-1.83) 
Former 59/59 1.30 (0.80-2.10)    83/105 1.04 (0.68-1.61) 
Current 20/26 0.90 (0.46-1.75)    25/ 34 0.79 (0.42-1.48) 
      
Never 73/91 1.00 (ref)    99/106 1.20 (0.78-1.83) 
<20 years 43/43 1.11 (0.65-1.91)    48/  67 0.80 (0.48-1.31) 
≥20 years 51/59 1.35 (0.78-2.33)    68/  91 1.03 (0.65-1.64) 
      
Never 73/91 1.00 (ref)    99/106 1.20 (0.78-1.83) 
<15 pack years 38/42 1.05 (0.61-1.81)    55/  68 0.91 (0.56-1.47) 
≥15 pack years 45/46 1.40 (0.82-2.40)    53/  71 1.15 (0.69-1.90) 
a adjusted for frequency matched factors age (indicator) and sex 
NOTE: persons smoking less than 100 cigarettes over lifetime were classified as never smokers 
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Table 4.5:  Joint effects of XRCC1 and ERCC1 and ERCC2 polymorphisms among whites 
Genotype Genotype Cases Controls OR (95% CI) P value 
XRCC1 399 ERCC1     
     AA      CC 80 96 1.00 (ref)  
     AA      AC/AA 78 84 1.14 (0.77-1.70)  
     AG/GG      CC 118 130 1.17 (0.75-1.82)  
     AG/GG       AC/AA 90 117 0.93 (0.62-1.41) 0.28 
      
XRCC1 399 ERCC2 156     
     AA      CC 47 45 1.00 (ref)  
     AA      AC/AA 99 124 0.83 (0.48-1.43)  
     AG/GG      CC 60 70 0.75 (0.45-1.24)  
     AG/GG      AC/AA 125 162 0.70 (0.44-1.14) 0.62 
      
XRCC1 399 ERCC2 751     
     AA      AA 61 66 1.00 (ref)  
     AA      AC/CC 90 106 0.90 (0.56-1.45)  
     AG/GG      AA 74 92 0.98 (0.62-1.54)  
     AG/GG      AC/CC 127 153 0.88 (0.58-1.52) 0.78 
Adjusted for frequency matched factors age (indicator) and sex 
 P value for interaction term in logistic model 
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CHAPTER V:   CONCLUSIONS 
 
A. Summary of findings 
    Our results agree with the suggestion that hormones may confer a protective effect against gliomas, but 
benefits may be limited to exogenous synthetic hormones.  Though the use of exogenous hormones appears to 
reduce the odds of glioma, the mechanism is unclear.  Our findings of no association with ages at menopause 
and menarche agree with the notion that circulating hormones originating from reproductive organs are likely to 
exert a relatively weak effect by the time it reaches the brain.  However, hormones produced in the brain by 
glial cells are thought to function at much higher concentrations since they act locally by autocrine/paracrine 
actions. Whether the effect of endogenous hormones originating in the brain is equivalent to the strength of 
synthetic hormones is unknown and difficult to tease out given hormones are irrelevant to the blood brain 
barrier.  The suggested dose-response association of oral contraceptive use among ever-users and the combined 
effects of separate exogenous hormones are favorable to high dose hormones as a potential preventative of 
gliomas, as demonstrated by the current strategy of high dose tamoxifen in glioma treatment.  However, our 
results cannot explain the established detrimental effects of estrogen in the formation of chromosomal adducts 
and generation of oxygen radicals in other somatic cells.  We acknowledge that our focus on estrogen as an 
explanatory variable for the gender predisposition of gliomas may be misdirected.  Rather, androgens may be 
driving the higher incidence rates among males.  Balancing the risks and benefits of hormones will require a 
better understanding of how hormones act in the nervous system, the androgenicity of exogenous hormones, the 
women who use exogenous hormone therapies, the time periods they use them in, and more detailed 
information on duration of use.  Hormones are likely just a small piece in this complex multifactorial disease as 
indicated by the modest risk estimates seen in this study.   
    Despite prior reports of an association between gliomas and NER repair genes polymorphisms, our data 
indicate that risk between gliomas and repair gene polymorphisms in the BER and direct repair pathway are 
minimal.  There was no evidence of interaction with DNA repair genotypes and smoking exposure which was 
surprising given genotypic risks are most relevant in the presence of highly mutagenic exposures.  The highly 
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efficient BBB may nullify the carcinogenic effects of smoking exposures, but the rare exposure to ionizing 
radiation is not likely to produce enough cases to adequately assess gene-environment interaction.  Although it 
is likely that repair genes are influential in glioma risk, their role in the etiology or development of gliomas will 
be difficult to tease out if damaged neuronal cells preferentially undergo apoptosis instead of repair, which may 
explain our otherwise unremarkable findings.  However, we have only examined three polymorphisms out of 
the potential hundreds that are involved in DNA repair and did not fully evaluate linkage disequilibrium which 
is likely to distort the effect of any single variant.       
B. Public health implications 
    Results from this study are not intended to change reproductive behaviors as a cancer preventive strategy 
since these behaviors are mainly driven by social and economic forces, nor are they intended to encourage 
genetic screening since identifying susceptible individuals with genetic variants may result in greater cost and 
potential individual harm than overall benefit.  Rather, the findings of this study are expected to provide critical 
leads to the etiology of brain tumors and implicate genetic pathways that would focus future investigations on 
exposures known to act through those pathways.  As an indirect benefit, findings will generally inform 
physician recommendation regarding OC and HRT use among women, which are often made with limited 
understanding to the effect these synthetic hormones may have on the initiation or progression of non-
reproductive cancers, such as brain cancer.  With an estimated 15 million postmenopausal women currently 
taking hormone therapy and another 11 million women using birth control pills in the United States, the 
potential impact on a population level would be significant.  Given that current treatment strategies have largely 
been ineffective, primary prevention is paramount.  Achieving prevention requires an understanding of the 
etiology of gliomas, which is yet poorly understood.  
C. Future directions 
 
    Given the relatively modest associations we saw in this and previous studies of reproductive factors, future 
studies may focus on further refining exposures.  However, since reproductive facts may not really reflect 
hormonal exposure, it is questionable whether further refinement of reproductive and menstrual variables will 
be productive.  Certainly information on cycle regularity and androgenicity of different hormone therapies may 
be informative, but until reproductive factors can be grouped into composite measures reflective of hormone-
specific exposure in the brain, risk estimates of future studies investigating reproductive factors and gliomas 
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will likely be underestimated, underpowered, and remain difficult to interpret.  If or when such composite 
measures are developed, future studies will be able to focus on whether low dose over a long period of time or 
high dose over shorter periods of time most impact risk.   
    Given the differing findings of cumulative exposure between our study of urban women and a previous study 
of rural women, further studies determining whether rural and urban residence impacts glioma susceptibility 
may be informative. With reproductive norms, values, and belief systems differing between rural and urban 
women, reproductive practices are expected to vary exposure levels between these two distinct areas.    
    Regarding DNA repair, future studies need to evaluate the many other polymorphisms within and between 
repair pathways to fully evaluate the impact of DNA repair function on gliomas.  Functional studies 
determining relevance of haplotypes and amino acid changes in SNPs are needed to understand the biological 
basis of repair gene-glioma associations.  SNP variants may demonstrate statistically significant risk estimates 
but be functionally irrelevant in relation to gliomas because they are in linkage disequilibrium with a true 
causative locus.  A haplotype-based analysis rather than a single SNP approach would capture more regional 
linkage disequilibrium information.  In addition, a haplotype-based analysis is more powerful since collecting 
information on all candidate SNPs suscepted to play a role in gliomagenesis may be redundant.  In the XRCC1 
and MGMT analyses, we were limited to collecting blood and buccal specimens from living participants.  More 
survival data would help clarify whether genotypes may be associated with survival.  Robust classifiers of brain 
tumor subtypes are needed other than histologic classification which can be somewhat subjective. Until we are 
able to consistently and accurately categorize gliomas, the ability to compare results between studies and 
meaningfully interpret findings is limited. 
    In general, SNPs have the advantage of being more prevalent in the population, but rarely have a meaningful 
effect apart from other strong environmental exposures.  Ionizing radiation is the only established 
environmental risk factor for gliomas, but currently there is no algorithm for assigning exposure based on dose 
and intensity, so we used smoking for purposes of this study.  Smoking has been inconsistently and only weakly 
associated with gliomas in previous studies.  A stronger mutagenic exposure such as ionizing radiation or 
another exposure yet unknown may prove more productive in gene-environment analyses.  
    The underlying premise of this study was to develop further hypothesis to whether the gender differences in 
gliomas could be explained, in part, by the interplay between DNA repair genes and hormones.  Molecular 
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studies indicate hormones may directly regulate DNA repair in hormonal cancers,1,2,3,4,5 and hormone-
independent cancers 6 but the mechanism is unclear.  Our study is a good first step toward justifying future 
studies evaluating this interaction, but more reliable surrogates of hormone exposure and identifying the 
functional role of XRCC1 and MGMT repair genes will be needed for meaningful interpretation of results.  
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Table A1: Reproductive and menstrual history questionnaire used in San Francisco Adult Glioma Study, 
Series 1 
 
D. Menstrual and Hormone Use History [FOR WOMEN; FOR MEN GO TO E, NEXT PAGE] 
1. At what age did you (did she) start menstruating?________ 
2. Are you still having periods, even infrequently? [FOR CASES: Were you (was she) having periods at 
diagnosis, even infrequently?]  9= DK [GO TO Q. 3.]  
1= Yes [GO TO Q. 3.]   [SPECIFY IF R IS UNCLEAR:________________ ] 
       2= No [IF MORE THAN ONE YEAR SINCE LAST PERIOD, CODE 'NO'] 
      a. How old were you (was she) when your (her) periods stopped completely: ______(age)?  
             [SHOW CARD H SECTION A]: 
    b. What caused your (her) periods to stop? 
1= went through natural menopause 
2= went through natural menopause then had hysterectomy 
3= had a hysterectomy, where both ovaries are intact 
4= had a hysterectomy, where both ovaries were removed 
5= had a hysterectomy, where at least 1/2 ovary remained 
6= oophrectomy, both ovaries removed, uterus is intact 
7= hysterectomy, type unknown 
8= underwent chemotherapy 
 10= other (specify): _____________________________________ 
9=   DK 
 
                            IF YES: 
  
3. Have you (Has she) ever taken: 
[FOR CASES: prior to diagnosis] 
What year 
did you start 
taking them? 
What was the 
very last year 
you took 
them? 
How many years/ 
months total did you 
take them, 
subtracting any time 
you did not take 
them? 
 
    years months 
a. Birth control pills: 1=Yes, now 
2=Yes, not now 
3=No, never 
9=DK 
    
b. Female hormones, other than birth 
control pills? 
SPECIFY:______________ 
_________________________ 
1=Yes, now 
2=Yes, not now 
3=No, never 
9=DK 
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Table A2: Reproductive and menstrual history questionnaire used in San Francisco Adult Glioma Study, 
Series 2 
 
B. Menstrual and Hormone Use History [FOR WOMEN; FOR MEN GO TO Part C] 
1. At what age did you (did she) start menstruating?________ 
2. Are you (is she) still having periods? [SHOW CARD C]  
1= Yes  
       2= Yes, but pregnant or postpartum now 
       3= Yes, but infrequently, probably perimenopausal 
       4= Yes, but taking menopausal estrogens now; How many months or years  
 have you (has she) been taking them? 
 _______________   _______________ 
         months       years 
       5= No, went through natural menopause: How old were you (was she) when  
 your (her) periods stopped completely?  ________ 
       6= No, had a hysterectomy 
           how old were you when this was done? 
    a. womb removed      age:__________ 
    b. womb and both ovaries removed  age:__________ 
    c. womb and 1 ovary removed   age:__________ 
    d. one/both ovaries removed only   age:__________ 
    e. hysterectomy: type unknown   age:__________ 
        7= No, never had periods 
        8= No, other: (SPECIFY)____________________________________ 
 
 
                  IF YES: 
  
3. Have you (Has she) ever taken: 
[FOR CASES: prior to diagnosis] 
What year 
did you start 
taking them? 
What was the 
very last year 
you took 
them? 
How many years/ 
months total did you 
take them, 
subtracting any time 
you did not take 
them? 
 
    years months 
a. Birth control pills: 1=Yes, now 
2=Yes, not now 
3=No, never 
9=DK 
    
b. Female hormones, other than birth 
control pills? 
SPECIFY:______________ 
_________________________ 
1=Yes, now 
2=Yes, not now 
3=No, never 
9=DK 
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Table A3:  Selected characteristics of female glioma cases and controls from the San Francisco Adult 
Glioma Study, stratified by series  
 Series 1 Series 2 
 Case (n=203) Control (n=209) Case (n=178) Control (n=185) 
    n          (%)    n          (%)    n          (%)    N          (%) 
 
Age (yrs) 
    
   20-44     61      (30)     66      (32)     45      (25)     49      (26) 
   45-54     21      (10)     29      (14)     32      (18)     38      (21) 
   55-64     34      (17)     34      (16)     35      (20)     30      (16) 
   65+     87      (43)     80      (38)     66      (37)     68      (37) 
   mean (sd)     56.6 (18.0)     55.5 (17.8)     57.1 (16.4)     56.1 (16.3) 
 chi square p = 0.53 chi square =0.56 
     
Race     
  White   177      (87)   180       (86)   148      (83)   161       (87) 
  Black       9      (  4)       8       (  4)       8      (  4)       6       (  3) 
  Asian       6      (  3)       6       (  3)       6      (  3)       4       (  2) 
  Hispanic/Mexican       8      (  4)       9       (  4)     12      (  7)     11       (  6) 
  Other       3      (  1)       6       (  3)       4      (  2)       3       (  2) 
 chi square p = 0.90 chi square p = 0.86 
     
Smoking 100 cigarettes     
  Never   102      (50)   111       (53)     95      (54)     88       (48) 
  Past     83      (41)     70       (34)     56      (32)     66       (36) 
  Current     17      (  8)     27       (13)     26      (15)     31       (17) 
  Missing       1      (  1)       1       (  0)       1      (  1)       0       (  0) 
chi square p =0.16 chi square p = 0.51 
     
Proxy     
 No   104      (51)   207       (99)   118      (66)   185       (100) 
 Yes     99      (49)       2       (  1)     60      (34)       0       (    0) 
 chi square p < 0.01 chi square p <0.01 
     
Education     
  High school or less   115     (57)   101       (48)     90    (51)     83      (45) 
  College     65     (32)     89       (43)     69    (39)     85      (46) 
  Graduate school/Professional     22     (11)     19       (  9)     17    (10)     16      (  9) 
  Missing       1      ( 0)       0       (  0)       2    (  1)       1      (  0) 
 chi square p = 0.04 chi square p =0.41 
     
Histologic Tumor Type   
Glioblastoma   126      (62)    102     (57)  
Astrocytoma     41      (20)      36     (20)  
Oligodendroglioma/ 
Oligoastrocytoma    
    28      (14)      32     (18) 
Other*       8      (  4)        8     (  4)  
     
Numbers do not always total to 100% due to rounding  
*other=ependymoma, juvenile pilocytic, astrocytoma, medulloblastoma, gangliogliomas, and not specified 
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Table A4: Selected characteristics of glioma cases and control among all females, and excluding proxies 
 
                Including Proxies              Excluding proxies 
      Cases    Controls       Cases   Controls 
         (n=381)    (n=394)      (n=222)    (n=392) 
       n           (%)           n        (%)   n           (%)          n          (%) 
 
Mean (SD) Age (yrs)  56.87 (17.23)    55.82 (17.09) 49.56 (15.77) 55.78 (17.11) 
 
Race 
   Caucasian   325 (85) 341 (87) 190 (86) 339 (86) 
   Black      17 (  4)   14 (  4)     9 (  4)   14 (  4) 
   Asian      12 (  3)   10 (  3)     7 (  3)   10 (  3) 
   Hispanic/Mexican    20 (  5)   20 (  5)   14 (  6)   20 (  5) 
   Other        7 (  2)     9 (  2)     2 (  1)     9 (  2) 
 
Menopausal Status 
   Premenopausal   125 (34) 153 (39) 111 (50) 153 (39)  
   Postmenopausal  248 (66) 241 (61) 111 (50) 239 (61) 
 
Education 
   High school or less  205 (54) 184 (47)   94 (42) 182 (46) 
   College   134 (35) 174 (44)   97 (44) 174  (45) 
   Graduate school/Professional   41 (11)   36 (  9)   31 (14)   35 (  9)  
   Missing       3        (  1)            1         (  0)           0         (  0)           1         (  0) 
 
Income 
   0-29,000   103 (27) 131 (33)   41 (18) 130 (33) 
   30,000-49,000     93 (24)   79 (20)   50 (23)   79 (20) 
   50,000-69,000     55 (14)   60 (15)   37 (17)   60 (15) 
   70,000-100,000+  107 (28) 110 (28)   83 (37) 109 (28) 
 
Smoking 100 cigarettes 
   Never    197 (52) 199 (50) 116 (52) 199 (51) 
   Past    139 (36) 136 (35)   81 (36) 134 (34) 
   Current     43 (11)   58 (15)   24 (11)   58 (15) 
   Missing       2        (  1)     1        (  0)     1         (  1)           1        (  0) 
  
Histologic Distribution 
   Glioblastoma   228 (60)     97 (44) 
   Astrocytoma     77 (20)     58 (26) 
   Oligodendroglioma/    60 (16)     53 (24) 
   Oligoastrocytoma 
   Other*     16 (  4)     14 (  6) 
 
Proxy 
   No    222 (58) 392 (99) 
   Yes    159 (42)     2 (  1) 
 
Numbers do not always total to 100% due to missings or rounding 
*other=ependymoma, juvenile pilocytic astrocytoma, medulloblastoma, gangliogliomas, and not specified 
 
 
 
 
 
 121
 
Table A5: Summary of reproductive factors and hormone use frequency and missingness 
  
Factors of reproductive 
and menstrual history 
and exogenous hormone 
use 
Frequency 
n  (%) 
Missings 
 n (%) 
Missings 
among cases 
 
Missings 
among 
controls 
     
MAIN EXPOSURES     
Parity Yes=609 (78.58) 
No =166 (21.42) 
0 0 0 
Number of kids  Range 1-11; median = 2 0 0 0 
Gravidity (series 1 only) Yes=106 (26.90) 
No=288 (73.10) 
18 (4.3) 16 (7.9)        2 (1.0) 
Age at first birth  Range 13-52, median = 
24 
2 (0.33) 2 (0.67) 0 
Age at menarche Range 8-18, median=13 70 (9.03) 66 (17.32) 4 (1.02) 
Age at menopause  Range 17-65, median=46 36 (7.36) 34 (13.71) 2 (0.83) 
Menopausal status Post: 489 (63.75) 
Pre: 278 (36.25) 
8 (1.03) 8 (2.10) 0 
Type of menopause Natural=300 (61.60) 
Surgical=172 (35.32) 
Other=15 (3.08) 
2 (0.41) 1 (0.40) 1 (0.41) 
Menstruation (Years) Range 5-72, median=33 70 (9.03) 66 (17.32) 4 (1.02) 
Birth control pill use Yes=403 (53.24) 
No=354 (46.76) 
18 (2.32) 17 (4.46) 1 (0.25) 
Birth control pill 
duration 
<2 years=109 (27.66) 
≥2 years=285 (72.34) 
9 (2.28) 9 (5.11) 0 
HRT use Yes=310 (41.22) 
No=442 (58.78) 
23 (2.97) 21 (5.51) 2 (0.51) 
HRT duration  <2 years=81 (27.65) 
≥2 years=212 (72.35) 
17 (5.80) 15 (11.81) 2 (1.09) 
     
COVARIATES     
Race White=666 (85.94) 
Other=109 (14.06) 
0 0 0 
Age Range=20-91; mean=56 0 0 0 
Smoking cigarettes Never=396 (51.16) 
Ever=378 (48.84) 
1 (0.13) 1 (0.26) 0 
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Table A6: Frequencies and odds ratios (95% CI) of reproductive factors among white glioma cases and controls, 
and restricted to self-reporting respondents  
 Cases    
Reproductive 
factors 
All females   
   (n = 325) 
    Index 
  (n = 190) 
Controls 
(n=341)τ 
OR (95% CI)Ψ OR (95% CI)Ψ 
among index 
Parity       
   Never 
   Ever 
     75   (23) 
   250   (77)  
     58   (31) 
   132   (69) 
     73   (21) 
   268   (79) 
   1.00 (ref) 
   0.88 (0.60-1.30) 
   1.00 (ref) 
   0.82 (0.53-1.26) 
Children      
   None 
   1 
   2 
   3+  
     75   (23) 
     56   (17) 
   100   (31) 
     94   (29) 
     58   (29) 
     35   (22) 
     62   (39) 
     61   (39) 
     73   (21) 
     64   (19) 
     97   (28) 
   107   (31) 
   1.00 (ref) 
   0.83 (0.51-1.35) 
   0.97 (0.63-1.51) 
   0.81 (0.51-1.28) 
   1.00 (ref) 
   0.74 (0.42-1.31) 
   0.83 (0.50-1.36) 
   0.88 (0.51-1.51)      
Gravidity (series 1)      
   Never 
   Ever 
   Missing 
   125   (71) 
     37   (21) 
     15   (  8) 
     67   (73) 
     18   (19) 
       7   (  8) 
   121   (67) 
     57   (32) 
       2   (  1) 
   1.00 (ref) 
   0.62 (0.38-1.02) 
   1.00 (ref) 
   0.68 (0.36-1.27) 
Age at first birth      
    ≤20 years old 
   21-25 years old 
   26-30 years old 
   30+ years old 
   Missing 
     53   (18) 
     97   (63) 
     58   (18) 
     41   (  1) 
       2   (  1) 
     30   (18) 
     44   (62) 
     36   (19) 
     22   (  1) 
       1   (  1) 
     52   (15) 
   113   (68) 
     68   (17) 
     35   (  0) 
       0   (  0) 
   1.00 (ref) 
   0.83 (0.52-1.33) 
   0.83 (0.50-1.40) 
   1.15 (0.64-2.08) 
      
   1.00 (ref) 
   0.68 (0.38-1.22) 
   0.90 (0.49-1.66) 
   1.01 (0.50-2.06) 
 
Age at menarche 
   ≤11 years old 
   12-13 years old 
   ≥14 years old 
   Missing 
 
     52   (16) 
   144   (44) 
     76   (23) 
     53   (16) 
 
     38   (20) 
   100   (53) 
     52   (27) 
       0   (  0) 
 
     64   (19) 
   188   (55) 
     87   (26) 
       2   (  1) 
 
   1.00 (ref) 
   0.94 (0.61-1.43) 
   1.17 (0.80-1.71) 
 
   1.00 (ref) 
   0.86 (0.53-1.39) 
   1.25 (0.81-1.93) 
Age at menopauseω      
   <45 years old 
   45-50 years old 
   50+ years old 
   Missing        
     65   (30) 
     67   (31) 
     57   (25) 
     30   (14) 
     28   (28) 
     36   (36) 
     28   (28) 
       8   (  8) 
     65   (30) 
     81   (38) 
     68   (31) 
       2   (  1) 
   1.00 (ref) 
   0.85 (0.53-1.38) 
   0.90 (0.54-1.50) 
   1.00 (ref) 
   1.16 (0.63-2.13) 
   1.26 (0.65-2.45) 
Menopausal statusδ      
   Premenopausal 
   Natural  
   Womb removed 
   Womb 1 ovary 
   Womb ovaries 
   Ovary(s) only 
   Other/unknown 
   Missing 
   101   (31) 
   120   (37) 
     13   (  4) 
     36   ( 11) 
     17   (  5) 
       2   (  1) 
     13   (  4) 
     23   (  7) 
     90   (47) 
     54   (28) 
       9   (  5) 
     19   (  1) 
       9   (  5) 
       1   (  1) 
       2   (  1) 
       6   (  3) 
   125   (37) 
   142   (42) 
     14   (  4) 
     34   (10) 
     16   (  5) 
       3   (  1) 
       5   (  1) 
       2   (  1) 
   1.00 (ref) 
   0.74 (0.44-1.22) 
   0.85 (0.37-1.96) 
   0.93 (0.49-1.76) 
   0.93 (0.41-2.09) 
   0.57 (0.09-3.64) 
   2.31 (0.76-7.01) 
   1.00 (ref) 
   1.28 (0.65-2.51) 
   1.70 (0.64-4.53) 
   1.96 (0.84-4.57) 
   1.87 (0.67-5.21) 
   1.15 (0.11-12.23) 
   1.25 (0.22-7.14) 
Menstruation yearsγ      
   <25 years 
   25-34 years 
   ≥35 years 
   Missing 
     68   (21) 
     96   (30) 
   108   (33) 
     53   (16) 
     68   (31) 
     85   (38) 
     69   (31) 
       0   (  0) 
     86   (25) 
   114   (33) 
   139   (41) 
       2   (  1) 
   1.00 (ref) 
   1.23 (0.78-1.94) 
   1.26 (0.75-2.10) 
    
   1.00 (ref) 
   1.32 (0.80-2.19) 
   1.43 (0.80-2.57) 
        
      
γ  Menstruation years = menopausal age  menarche age.  Reproductive period was linear in logit but categorized here for demonstrable 
purposes. 
δ Eight women self-reported they were still having a menstrual period, but were taking menopausal hormones.  These 8 (1.94%) were 
classified as premenopausal since natural hormones were hypothesized to have a stronger effect than exogenous hormones.  This, in fact, may 
be wrong, but given the small number of women in this group, estimates are not expected to be impacted by possible misclassification. 
ω Among postmenopausal women 
Ψ Adjusted minimally for age (continuous) and race (binary) 
τ Two controls were proxies and were accounted for in the adjusted OR for index respondents 
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Table A7: Frequencies and odds ratios (95% CI) of exogenous hormone use among white glioma cases and 
controls, and restricted to self-reporting respondents 
 Cases    
Exogenous 
hormones factors 
All females 
(n=325) 
n   (%) 
Index  
(n = 190) 
n    (%) 
Controls 
(n=341)τ 
   
OR (95% CI)Ψ OR (95% CI)Ψ 
among index 
Oral contraceptive 
use 
      
   Never 
   Ever 
   Missing 
   157   (48) 
   154   (47)  
     14   (  4) 
     68   (36) 
   122   (64) 
       0   (  0) 
   145   (42) 
   195   (58) 
       1   (  0) 
   1.00 (ref) 
   0.62 (0.42-0.91) 
   1.00 (ref) 
   0.79 (0.51-1.24) 
      
Oral contraceptive 
duration (years) 
     
   ≤ 2 years 
   2-4 years 
   5-9 years 
   ≥10 years 
   Missing     
     34   (22) 
     48   (31) 
     34   (22) 
     30   (19) 
       8   (  5) 
     31   (25) 
     41   (34) 
     27   (22) 
     21   (17) 
       2   (  2) 
     56   (29) 
     36   (18) 
     46   (24) 
     57   (29) 
       0   (  0) 
   1.00 (ref) 
   1.65 (0.91-2.99) 
   0.76 (0.41-1.43) 
   0.40 (0.19-0.82) 
    
   1.00 (ref) 
   1.55 (0.83-2.90) 
   0.69 (0.35-1.34) 
   0.48 (0.22-1.04)* 
 
         
Female hormone 
use ω 
     
   Never 
   Ever 
   Missing 
   101   (46) 
   105   (48) 
     13   (  6) 
     45   (45) 
     54   (54) 
       1   (  1) 
     72   (33) 
   142   (66) 
       2   (  1) 
   1.00 (ref) 
   0.50 (0.34-0.75) 
   1.00 (ref) 
   0.54 (0.32-0.90) 
        
Female hormone 
duration (years) ω 
     
   <2 years 
   2-4 years 
   5-14 years 
   ≥15 years 
   Missing 
     14   (13) 
     24   (23) 
     24   (23) 
     30   (29) 
     13   (12) 
       8   (15) 
     15   (28) 
     15   (28) 
     14   (26) 
       2   (  3) 
     37   (26) 
     24   (17) 
     35   (25) 
     45   (32) 
       1   (  1) 
   1.00 (ref) 
   2.49 (1.07-5.79) 
   0.74 (0.34-1.61) 
   1.02 (0.51-2.07) 
   1.00 (ref) 
   2.28 (0.80-6.47) 
   0.92 (0.36-2.33) 
   0.91 (0.38-2.19) 
      
Cumulative 
exposure γ 
   ≤312 months 
   313 - 407  
   408 - 503  
   ≥504  
  
 
     73   (22) 
     52   (16) 
     88   (27) 
     59   (18) 
     53   (16) 
 
     64   (33) 
     36   (19) 
     62   (33) 
     28   (15) 
       0   (  0) 
 
     80   (23) 
     71   (21) 
     94   (26) 
     94   (26) 
       2   (  1) 
 
   1.00 (ref) 
   0.88 (0.52-1.49) 
   1.19 (0.69-2.06) 
   0.82 (0.45-1.51) 
 
   1.00 (ref) 
   0.97 (0.55-1.74) 
   1.62 (0.87-2.99) 
   0.85 (0.41-1.73) 
      
γ  Cumulative exposure = menopausal age  menarche age + duration of postmenopausal hormone use.   
ω Among postmenopausal women 
Ψ Adjusted minimally for age (continuous) and race (binary) 
τ Two controls were proxies and were accounted for in the adjusted OR for index respondents 
* p for trend = 0.01 
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Table A15:  Distribution of genotypes among glioma cases and cancer free controls, and restricted to whites 
 
          All study subjects                 White subjects only            
Cases (n=873)  Controls (n=864)              Cases (n=723)   Controls (n=723) 
     n        (%)   n        (%)  n         (%) n         (%) 
 
 
XRCC1 (Arg399Gln) 
   GG   198     (44.9) 214     (43.9)  158     (43.2) 180     (42.2)  
   AG   186     (42.2) 219     (45.0)  155     (42.3) 196     (45.9) 
   AA     57     (12.9)   54     (11.1)    53     (14.5)   51     (11.9) 
   Total   441     (50.5) 487     (56.4)  366     (50.6) 427     (59.1) 
 
ERCC1 (C8092A) 
   CC   238     (52.9) 267     (52.6)  198     (54.1) 226     (52.9) 
   AC   176     (39.1) 212     (41.7)  143     (39.1) 179     (41.9) 
   AA     36     (  8.0)   29     (  5.8)    25     (  6.8)   22     (  5.2) 
   Total   450     (51.5) 508     (58.8)  366     (50.6) 427     (59.1) 
 
ERCC2 (Arg156Arg) 
  CC   137     (32.7) 155     (29.9)  107     (32.3) 115     (28.7)  
  AC   200     (47.7) 261     (50.3)  158     (47.7) 208     (51.9) 
  AA     82     (19.6) 103     (19.8)    66     (19.9)   78     (19.5) 
  Total     419     (48.0) 519     (60.1)  331     (45.8) 401     (55.5) 
 
ERCC2 (Lys751Gln)  
  AA   190     (43.0) 201     (40.7)  135     (38.4) 158     (37.9) 
  CA   189     (43.0) 235     (47.6)  160     (45.5) 207     (49.6) 
  CC     63     (14.3)   58     (11.7)    57     (16.2)   52     (12.5) 
  Total   442     (50.6) 494     (57.2)  352     (48.7) 417     (57.8) 
 
MGMT (Leu84Phe) 
  CC   377     (78.0) 388     (78.4)  310     (77.5) 315     (78.2)  
  CT   104     (21.0)   94     (19.0)    88     (22.0)   80     (19.8) 
  TT       3     (  1.0)   13     (  2.6)      2     (  0.5)     8     (  2.0) 
  Total   484     (55.4) 495     (57.3)  400     (55.3) 403     (55.7) 
 
MGMT (Ile143Val) 
  AA   393     (83.4) 386     (80.7)  322     (82.6) 319     (82.0) 
  AG     77     (16.3)   84     (17.6)    67     (17.2)   66     (17.0) 
  GG       1     (  0.2)     8     (  1.7)      1     (  0.2)     4     (  1.0) 
  Total   471     (54.0) 478     (55.3)  390     (53.9) 389     (53.8) 
 
 
*numbers do not always total 100% due to missings or rounding 
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Table A16: Frequencies and odds ratios (95% CI) for  XRCC1 Arg399Gln, MGMT Leu84Phe, and MGMT 
Ile143Val polymorphisms and gliomas among whites, stratified by age 
XRCC1 Cases (n=366) 
  n   (%) 
Control (n=427) 
            n    (%) 
Adjusted OR ω  
(95% CI) 
Breslow-Day 
p values 
<45 years old     
  Arg/Arg 55  (15) 39  (  9)   1.00 (ref)  
  Arg/Gln + Gln/Gln 69  (19) 66  (15)   0.74 (0.44-1.26)  
45-54 years old     
  Arg/Arg 35  (10) 46  (11) 1.00 (ref)  
  Arg/Gln + Gln/Gln 49  (13) 45  (11) 1.46 (0.80-2.67)  
55-64 years old     
  Arg/Arg 37  (10) 32  (  7) 1.00 (ref)  
  Arg/Gln + Gln/Gln 38  (10) 50  (12) 0.66 (0.35-1.24)  
65+ years old     
  Arg/Arg 31  (  8) 63  (15) 1.00 (ref)  
  Arg/Gln + Gln/Gln 52  (14) 86  (20) 1.21 (0.69-2.10) 0.19 
     
MGMT 84 Cases (n=443) 
n    (%) 
Control (n=434) 
            n     (%) 
Adjusted OR ω 
(95% CI) 
Breslow-Day 
p value 
<45 years old     
   Leu/Leu 87  (20) 88  (20)   1.00 (ref)  
   Leu/Phe + Phe/Phe 27  (  6) 19  (  4)  1.37 (0.74-2.53)  
45-54 years old     
   Leu/Leu 71  (16) 71  (16) 1.00 (ref)  
   Leu/Phe + Phe/Phe 19  (  4) 15  (  3) 1.16 (0.57-2.36)  
55-64 years old     
   Leu/Leu 65  (15) 59  (14) 1.00 (ref)  
   Leu/Phe + Phe/Phe 21  (  5) 20  (  5) 0.96 (0.46-2.01)  
65+ years old     
   Leu/Leu 126  (28) 128  (29) 1.00 (ref)  
   Leu/Phe + Phe/Phe 27  (  6) 34  (  8) 1.54 (0.81-2.93) 0.81 
     
MGMT 143 Cases (n=418) 
n    (%) 
Control (n=427) 
      n     (%) 
Adjusted OR ω 
(95% CI) 
P value 
<45 years old     
   Ile/Ile 82  (20) 87  (20) 1.00 (ref)  
   Ile/Val + Val/Val 19  (  5) 19  (  4) 1.07 (0.56-2.05)  
45-54 years old     
   Ile/Ile 66  (16) 67  (16) 1.00 (ref)  
   Ile/Val + Val/Val 20  (  5) 13  (  3) 1.00 (0.45-2.22)  
55-64 years old     
   Ile/Ile 67  (16) 70  (16) 1.00 (ref)  
   Ile/Val + Val/Val 16  (  4)   8  (  2) 2.47 (1.12-5.45)  
65+ years old     
   Ile/Ile 120  (29) 134  (31) 1.00 (ref)  
   Ile/Val + Val/Val   28  (  7)   29  (  7) 0.99 (0.52-1.90) 0.28 
     
ω adjusted for frequency matched factors sex 
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